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Abstract
Messenger RNA degradation is a major control point in determining the abundance of 
mRNA, and hence in the regulation of gene expression. Until recently, endoribonucleases, 
enzymes that cleave the phosphodiester bond within a polynucleotide chain, have been 
dismissed as the key enzymes responsible for mRNA turnover. The human 
apurinic/apyrimidinic endonuclease 1 (APE1) was recently identified as an endoribonuclease 
that is capable of cleaving c-myc mRNA in vitro and regulate c-myc mRNA level and half- 
life in cells. The ability to subject any target mRNA for degradation is a powerful 
therapeutic intervention, and the technologies currently in use have employed activities of 
endoribonucleases. Hence, in addition to increasing our basic knowledge on its role in the 
regulation of gene expression, a better understanding on the RNA-degrading enzyme such as 
APE1 has the potential in leading to the development of novel gene inactivation technology.
The first objective of this thesis was to determine whether APE1 possesses 3 'RNA 
phosphodiesterase and 3'-5' exoribonuclease activities. Using three different RNA 
substrates, we confirmed that APE1 indeed has 3 'RNA phosphodiesterase activity which is 
clearly absent in the common Ribonuclease A. We also found that Myricetin, a known 
inhibitor of AP-DNA activity, is capable of inhibiting 3 'RNA phosphodiesterase activity of 
APE1. Our results also revealed that APE1 has weak to negligible 3'-5' exoribonuclease 
activity against unstructured poly-ribonucleotides. However, as with its known 3 'DNA 
exonuclease activity, we found that APE1 has preferential in removing one nucleotide at 
3 'overhang of RNA.
The second objective of this thesis was to determine the critical amino acids 
responsible for the 3' RNA phosphodiesterase activity of APE 1. Our results revealed that 
APE1 uses several similar critical residues in carrying out both its endoribonuclease and 3' 
RNA phosphodiesterase activities. However, few amino acid residues are critical for 3' RNA 
phosphodiesterase activity, suggesting that the catalytic mechanisms for these two 
ribonuclease activities are distinguishable. We also assessed the 3 ' RNA phosphodiesterase 
activity of APE1 variants identified in the human population. The tested population variants 
of APE1 exhibited significant reduction in both endoribonuclease and 3' RNA 
phosphodiesterase activities, further highlighting the possible unrecognized link between
RNA-cleaving activities of the variants and their reported association in certain diseases. 
Using a 34-mer abasic RNA as substrate, we also investigated the critical amino acid residues 
responsible for the abasic RNA incision activity of APE1. Preliminary results revealed that 
for a few variants, the endoribonuclease activities were severely reduced while retaining their 
AP-RNA incision activity. This suggests that the catalytic mechanism is different for the 
endoribonuclease and abasic RNA activities of APE1.
In summary, this research has demonstrated for the first time the 3' RNA 
phosphodiesterase and 3'-5' exoribonuclease activities of APE1. To our knowledge, this is 
the first report of a single polypeptide enzyme with endoribonuclease, 3 'RNA 
phosphodiesterase and 3'-5' exoribonuclease activities. This further underscores the 
significance of understanding the role of APE1 in RNA metabolism in vivo.
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CHAPTER 1 -  BACKGROUND
CHAPTER 1
Background
1.1 Introduction
Apurinic/apyrimidinic endonuclease 1 (APE1) is a well-established nuclear protein 
known to possess nuclease activity against DNA. For instance, APE1 possesses 3'-5 ' DNA 
exonuclease and 3' DNA phosphodiesterase activities. The human APE1 has also been 
identified as an endoribonuclease that can influence c-myc mRNA levels and half-life in cells 
(Barnes et al. 2009). However, the 3 'RNA phosphodiesterase and 3 'exoribonuclease 
activities of this enzyme have not been investigated. Thus, the primary focus of this thesis 
was to assess whether human APE1 possesses 3' RNA phosphodiesterase and 
3'exoribonuclease activities in vitro. This chapter provides broad background information on 
gene expression as well as currently known biochemical properties of APE1 and APE1 
variants.
1.2 mRNA Degradation in the Control of Gene Expression
In eukaryotes, mRNA stability or turnover plays a key role in the control of gene 
expression (Parker et al. 2004). Small changes in mRNA stability can result in a magnitude 
of difference in mRNA abundance in a cell thus directly controlling the abundance of the 
corresponding protein (Fan et al. 2002; Raghavan et al. 2002; Ross et al. 1995). mRNA 
turnover or degradation is an important gene regulatory pathway that ensures high accuracy 
of mRNA levels and increases the quality control of mRNA biogenesis and gene expression 
(Bettegowda and Smith 2007). The following sections examine the various pathways 
involved in the control and processes governing mRNA degradation. There are also several 
other decay pathways that exist in what are termed as mRNA-surveillance mechanisms.
These mechanisms function at various steps of the mRNA biogenesis pathway to detect and 
degrade transcripts that have not properly been processed (Gameau et al. 2007).
1.3 General mechanisms & pathways of messenger RNA decay
mRNA degradation pathways and quality control mechanisms governing RNA decay 
and processing have seemingly been established in bacteria, lower eukaryotes and higher
1
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eukaryotes; albeit to a lesser extent. It is generally considered that, following deadenylation, 
mRNA decay in yeast and mammalian cells occurs primarily via two exonucleolytic 
pathways, either in the 5'-to-3' or 3'-to-5' direction (Figure 1) (Li et al. 2010, Tafech et al. 
2006). In yeast (predominantly using Saccharomyces cerevisiae) mRNA degradation can be 
initiated by deadenylation either by Poly A Ribonuclease (PARN) or CCR4b-NOT, which 
shorten the poly (A) tail at the 3' end of the mRNA (Figure 1). On the other hand, mRNA 
degradation can also begin by the removal of 5' cap by a decapping enzyme consisting of 
two subunits, Dcplp and Dcp2p, which removes the 7'- methylguanosine cap (m7G) (Figure 
1) (Parker et al. 2004) . Following either of the aforementioned processes, the exposed 
transcript can then be digested by a 5'-3' exoribonuclease (ExoRNase), Xmlp, or by a 3'-5' 
exosome (Schaeffer et al. 2009; Parker et al. 2004). The composition of the mammalian 
exosome is very similar to that of yeast, suggesting that the 5 '-3' degradation pathway has 
similar components to that of 3 '-5 'decay, which is also conserved in mammals (Gameau et 
al. 2007). To provide further support that the 5 '-to-3' and 3 '-to-5' decay pathways are both 
important in mRNA degradation in mammals, there is evidence of the presence of decay 
intermediates involved in both pathways (Gameau et al. 2007).
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Figure 1. Schematic diagram of exoribonucleolytic and endoribonucleolytic decay pathway that 
control mammalian mRNA stability. (A) Two exonucleolytic pathways: (i) Following deadenylation, 
shortening of polyA tail as the initial step of 3'-5' mRNA exoribonucleolytic decay; (ii) Removal of 
5'-cap by decapping proteins decreases the vulnerability to degradation. (B) Endoribonuclease 
cleaves mRNA in the middle and accelerates further degradation of target mRNA (C) Following 
either of the aforementioned processes, further degradations are executed by 3 '-5' or 5 '-3' 
exoribonucleases, for instance the exosome or Xmlp, respectively (Parker and Song 2004; Gameau et 
al. 2007).
2
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Until recently, it has generally been considered that mRNA decay in higher 
eukaryotes occurs primarily through the ends of RNA molecules by the action of 
exonucleases. A growing amount of research on endoribonucleases, enzymes responsible for 
internal cleavage of RNA, has begun to challenge this view (Li et al. 2010). Unfortunately, 
much of their cellular functions remain poorly understood. EndoRNases that cleave 
vertebrate mRNA are: Ras GTPase-activating protein that cleaves between cytosine and 
adenine residues at 3 '-UTR of c-myc mRNA in mice; PMR1 cleaves albumin and 
vitellogenin mRNAs; and ARD-1 that is only known to have functional homology to RNase 
E (Li et al. 2010). In addition, a few mammalian endoRNases (RNase L, Irel, Dicer, and 
Argonaute2) have been identified to degrade mRNA only during cellular physiological 
crises, but their ability to degrade mRNA under normal physiological situations is unknown 
(Li etal. 2010).
1.4 Factors involved in mRNA stability
For higher eukaryotes, studies have indicated that physiological and environmental 
conditions can affect mammalian mRNA turnover rates (Guhaniyogi et al. 2001; Ross 1995). 
This is exemplified by studies using cDNA arrays on T-cell activation (Raghavan et al. 2002) 
and UV irradiated cells (Fan et al. 2002) which showed a degree of difference between 
mRNA stability and mRNA abundance within the cells (Ross et al. 1995). Earlier studies in 
this field have shown that the stability of mRNA can be influenced by cw-acting elements 
such as the poly (A) tail and AU-rich elements (AREs), and frans-acting factors such as non­
coding RNAs (ncRNAs), RNA-binding proteins (RBPs), and ribonucleases (RNases) (Li et 
al. 2010; Kim etal. 2009).
1.4.1 Decapping Enzymes
Well-studied decapping enzymes such as mRNA-decapping enzyme subunit 1 (Dcpl) 
and mRNA-decapping enzyme subunit 2 (Dcp2) are required for the removal of the 
protective cw-regulatory elements 5'- m7G and 3'- poly (A) tail (Gameau et al. 2007). 
Removal of these elements leads to degradation by the conventional exoribonucleolytic 
pathways, which degrade mRNA molecules from either the 5' or 3' ends. Dcplp/Dcp2p 
complex is conserved between yeast and mammals and is capable of decapping mRNAs as
3
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shown by hDcp2 and Dcpl protein that co-immunoprecipitated with the decapping activity 
(Decker and Parker 2002). The predominant mechanism of mRNA decay in yeast involves 
deadenylation (shortening of the poly (A) tail). The mRNA deadenylases, involved in the 
removal of the 3' poly (A) tail in mammalian cell, are the dual functional proteins such as 
PARN (Dehlin et al. 2000) and CCR4-NOT (Chen et al.2002). The deadenylation process is 
then followed by decapping with Dcplp, Dcp2p, and then the exposed transcript is subjected 
to degradation in either 5 '-3' direction by Xmlp and Ratlp in eukaryotic cells (Gameau et 
al. 2007; Schaeffer et al. 2009); or 3'-5' direction by an exosome which is a complex that 
consists of various 3'-5' exoribonucleases, several accessory proteins, and RNA helicases 
(Parker and Song 2004).
1.4.2 RNA-binding proteins (RBPs)
RNA-binding proteins (RBPs) play key roles in post-transcriptional control of gene 
expression. They are known to bind with mRNA molecules, either in the untranslated 
regions or in the protein coding region. RBPs influence the structure and interactions of the 
RNAs and play critical roles in their biogenesis, stability, function, transport and cellular 
localization. The RBPs not only influence each of these processes, but also provide a link 
between them (Hilleren et al. 2001; Kyburz et al. 2006; Millevoi et al. 2006; Rigo et al.
2008; Glisovic et al. 2008). Proper functioning of these intricate networks is essential for the 
coordination of complex post transcriptional events, and their irregularity can lead to genetic 
disorders.
RBPs form dynamic interactions with coding, untranslated and non-protein-coding 
RNAs in functional units called ribonucleoprotein (RNP) complexes. mRNA protein 
complexes (mRNPs) undergo a series of re-modeling events that are influenced by translation 
and/or mRNA decay machinery. One well-studied instability element is the AU-rich element 
(ARE) present in the 3'-untranslated region (UTR) of a subset of unstable mammalian 
mRNAs. Many ARE-binding proteins have been identified that act to increase the half-life of 
the mRNA by blocking the effects of mRNA degrading machinery in the cell, therefore 
increasing the mRNA levels (Wilusz et al. 2001). A study using breast cancer cell lines 
showed that HuR significantly mediates the over-expression of an oncogenic biomarker by 
enhancing its mRNA half-life (Guo and Hartley 2006; Sobue et al. 2008); while another
4
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study reported that HuR can stabilize tumor suppressor mRNA in prostate cancer cell lines 
(Quan et al. 2007; Bandyopadhyay et al. 2008). Also, another RNA-binding protein called 
Coding Region Determinant-Binding Protein (CRD-BP) is known to shield a number of 
mRNAs from degradation (Ioannidis et al. 2005).
1.4.3 Ribonucleases (RNases)
Ribonucleases (RNases) are a group of enzymes that play an important role in the 
regulation of mRNA levels. They are capable of cleaving RNAs at phosphodiester bonds 
resulting in remarkably diverse biological consequences. RNases can be classified into two 
mRNA degradation pathways: those catalyzed by the exoribonucleases (ExoRNases) and 
those catalyzed by the endoribonucleases (EndoRNases). RNases have been identified as 
being involved directly (CCR4b can induce cancer; XRN1 and RNase L both suppress 
cancer) or indirectly (Argonaute2, Dicer, and RNase A) in mRNA decay. The biochemical 
activities of the indirect RNases have been used to control the regulation of certain mRNAs, 
in particular, those implicated in certain human cancers (Kim and Lee 2009). Currently, 
there are only two RNases (bovine seminal RNase and Ranpimase) that have been evaluated 
directly as potential therapeutic agents against cancer (Lee and Raines 2008).
Exoribonucleases and their association with disease
In the past, exoribonucleases were thought to be the major players in RNA 
degradation in which the mRNA molecule is degraded from the 5' end, following decapping, 
or from the 3' end, following deadenylation (Houseley et al. 2009). There are four major 
classes of characterized 3 'to 5' exoribonucleases: the RNR, DEDD, and PDX superfamilies 
that are well conserved between eukaryotic, archaeal, and bacterial kingdoms (Ibrahim et al. 
2008; Zuo, et al. 2001). Specifically for this study, 3'-5' exoribonucleases that are conserved 
in all higher eukaryotes (Ibrahim et al. 2008) are summarized in Table 1. To help understand 
the important role of each mRNA decay pathway and the general issues on how mRNA is 
regulated, it is necessary to recognize and study the enzymatic machinery of mRNA 
degradation.
5
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Table 1: Summary of 3 '-5' exoribonucleases.
Superfamily E.coli members S. cerevisiae members
Substrate
Specificity Catalytic Features
RNR
RNase II 
RNase R Not identified
ssRNA 
2° RNA
• 3 '-5 'Hydrolytic
• Two metal ion 
dependent 
phosphodiesteraseNot identified
Rrp44 (Dis 3) 
Msul (Dss 1) 
Ssdl
ssRNA
DEDD
RNase D Rrp6 small stable RNA • 3 '-5 'Hydrolytic
• Two metal ion 
dependent 
phosphodiesterase
• RNase T: metal 
independent 
phosphodiesterase
RNase T Not identified ssRNA 1-2 nt
Oligoribonuclease Ynt20 (Rex 2) oligos 2-7 nt
Not identified
Pan 2 
Rex 1, 3, 4 
CCR4 
PARN
3' poly (A) RNA
PDX
APNPase Not identified c-myc RNA dsRNA
• 3'-5' 
Phosphorolytic
• Two metal ion 
dependent 
phosphodiesterase
RNase PH 
(core of exosome)
Rrp41 - 43,45, 
46 
Mtr3
ssRNA
Exoribonucleases cleave phosphodiester bonds through either a hydrolytic or a 
phosphorolytic mechanism resulting in production of nucleotide monophosphates or 
nucleotide diphosphates, respectively, starting at either the 5'- or 3'- end of an RNA strand 
(Ibrahim et al. 2008). They usually do not recognize specific RNA targets but degrade any 
RNA that is single-stranded (Gerlt et al. 1993). However, even if a 3'overhang (linear 
stretch) is provided to initiate degradation and exoribonucleases are able to bind RNA, they 
may detach upon approaching stem-loops (Ibrahim et al. 2008; Andrade et al. 2009). To 
date, only RNase R is able to overcome highly folded structures on its own (Andrade et al. 
2009). A specific example of a 5' to 3' exoribonuclease is XRN1, a key enzyme responsible 
for subsequent decay of the body of majority of mRNAs (Mitchell et al. 1997). There has 
been suggestion that XRN 1 may act as a tumour suppressor gene in osteogenic sarcoma 
(Mullen et al. 2008). The 3' to 5' decay pathway is believed to be predominantly mediated 
by the conserved exosome, a complex of proteins that include RNA-binding proteins, a
6
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helicase and 3'-5' exoribonucleases (Ibrahim et al. 2008). The yeast exosome complex has 
homologs in the human complex, both having sequence similarity to bacterial 
exoribonucleases (RNase PH, D or R) (Deutscher et al. 2001; Ibrahim et al. 2008). Thus, it 
appears that like the 5'-3' degradation machinery, 3 '-5' decay components are also 
evolutionarily conserved. Furthermore, exosomes are considered to play an important role in 
diagnosis and biomarker studies in tumorigenesis (Neil et al. 2006; Gusachenko et al. 2013). 
Another specific example of a 3 ’-5' exoribonuclease is the previously mentioned PARN 
protein (Martinez et al. 2001); when coupled with destabilizing actions of RBPs, PARN can 
potentially act as a tumor suppressor, causing degradation of mRNAs encoding growth 
factors such as IL-8 and VEGF (Suswam et al. 2008). Also, the evolutionarily conserved 
CCR4 protein, is a catalytic component of the cytoplasmic mRNA deadenylase that displays 
a preference for 3 exoribonucleolytically degrading RNA and 3' poly(A) substrates (Chen et 
al. 2002); the chemokine receptor CCR4 is particularly expressed on certain immune cells 
and some hematological tumor cells, which play a vital role in suppression of host immune 
response (Yang et al. 2011). Importantly, like the 5 '-3' degradation mechanism, 3 '-5 ' decay 
components are also evolutionary conserved.
The essential characteristics of both the enzymes and RNA substrate seem to control 
the degradation of individual RNAs. However, some common features are evident from the 
analysis of different RNA degradation pathways. Polyadenylation emerges as an important 
factor controlling exonucleolytic activity (Dreyfus et al. 2002). Disruption of RNA structural 
features may also work as an efficient accessibility of RNases, i.e., exposing the 3' RNA end 
to exonucleolytic attack. For instance, following endonucleolytic cleavages, the linear 
transcripts are quickly degraded by the 3'-5' degradative exoribonucleases, i.e., RNase II, 
RNase R, and PNPase (Andrade et al. 2009). A minor pathway in the cell is the 
exonucleolytic degradation of full-length transcripts. The short 3 ' overhang usually found 
downstream of the transcription terminator can be extended by poly (A) polymerase (PAP 1). 
Polyadenylation promotes RNA degradation by providing a grip to which exoribonucleases 
can bind. Cycles of polyadenylation and exonucleolytic digestion can overcome RNA 
secondary structures. RNase R is more efficient against highly structured RNAs provided 
there is a single-stranded 3' overhang of more than 7 to 10 nucleotides in length (Vincent et 
al. 2006). PNPase in association with other proteins namely RNA helicases, can also unwind
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RNA duplexes (Lin PH et al. 2005; Carpousis et al. 2007). The small oligoribonucleotides 
(2 -5 nucleotides) released by exoribonucleases are finally degraded to mononucleotides by 
oligoribonuclease that requires a free 3'-OH end, but is not sensitive to the 5' 
phosphorylation state of the RNA (Datta et al. 1975).
Endoribonucleases and their association with disease
Research continues to discover and highlight the importance of endoribonuclease- 
mediated mRNA decay pathways and their role in gene expression. The mode of action for 
endoribonucleases implies that they can cleave aberrant transcripts internally in-order to 
bypass both decapping and deadenylation steps and in theory, are much more efficient than 
exoribonucleases (Kim et al. 2009). Some cellular endoribonucleases that have been 
characterized in recent years are RNase L, IRE1, PMR1, Dicer, Ago2, RNase A, and APE1 
(Li et al. 2010; Tomecki et al. 2010). A few of these endoribonucleases (RNase L, DRE1, 
and PMR1) have been found to be tightly controlled through cellular signals, so that cells can 
efficiently respond to the changes in its environment by regulating gene expression at its 
mRNA level; and other identified endoribonucleases (Dicer, Ago2, and RNase A) have 
distinct functions in eukaryotic cells owing to their endoribonuclease activity.
1.4.4 3' RNA Phosphodiesterases
Nucleases cleave the phosphodiester bonds of nucleic acids and may be endo or 
exo, DNase or RNase, topoisomerases, recombinases, ribozymes, or RNA splicing enzymes. 
Thus, nucleases, members of a larger class of phosphodiesterases, hydrolyze nucleic acids by 
transfer of nucleotidyl groups to a hydroxyl group of water. Nuclease activities are essential 
in RNA processing, maturation and RNA interference (Abelson et al. 1998; Chu and Rana, 
2007; Moore and Proudfoot, 2009; Nowotny and Yang, 2009). RNA and DNA degradation 
are essential components of microbial defence mechanisms (James et al. 1996; Sorek et al. 
2008; Tock and Dryden, 2005). Nucleases are even essential for programmed cell death 
(Parrish and Xue, 2006). Defective DNase and RNase activities have been associated with 
various autoimmune diseases due to an incomplete removal of endogenously produced 
nucleic acids (Crow and Rehwinkel, 2009; Stephenson, 2008). In this section, the basic 
chemistry for nucleolytic reactions, generation of 3'-phosphate (PO42 ) and 3 '-hydroxyl (OH)
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group products, followed by an example of a catalytic mechanism (i.e., RNase A and RISC) 
that generate each of the 3 'end products are briefly introduced.
Catalytic Mechanism
Phosphodiesterases are nucleases that cleave one of the two bridging phosphate 
bonds, 3' or 5', in a nucleic acid polymer (Figure 2). Cleavage of phosphodiester bonds is 
thought to be done by a general acid—base catalysis, where the general base activates the 
nucleophile by deprotonation and the general acid facilitates product formation by 
protonating the leaving group. Perhaps because of the stability of nucleic acid phosphodiester 
bonds, the cleavage reaction is usually of the associative bimolecular nucleophilic 
substitution (S n2 ) type (Gerlt et al. 1983). The reaction can be divided into three stages: 
nucleophilic attack, the formation of a highly negatively charged penta-covalent intermediate 
and the breakage of the scissile bond. Cleavage of the P -03 ' bond, which generates 5 '- 
phosphate and 3'-hydroxyl products, requires a nucleophile to be on the 5' side hanging for 
the in-line attack (Figure. 2a). In the penta-covalent bi-pyramid intermediate, the 0 5 ' moves 
to the center plane, which consists of the phosphorus and two non-bridging oxygens, and the 
attacking nucleophile and 0 3 'leaving group, are opposite each other at the top of the bi­
pyramid. In the cleaved product, the stereo configuration of the phosphorus is inverted in this 
one-step reaction (Eckstein, 1985; Gerlt et al. 1983). Hence, the two non-bridging oxygens 
are referred to as pro-Sp and pro-Rp. A double inversion, which returns the phosphorus to its 
original configuration, requires a two-step reaction and occurs if an enzyme-nucleic acid 
covalent intermediate forms (Figure. 2b). To generate 3'-P04 and 5'-0H products, the 
reaction configuration has to be reversed, and the nucleophile has to attack on the 3' side of 
the scissile phosphate (Figure. 2a).
9
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Figure 2. Adjacent nucleotides in RNA are linked by 3 and 5' O-P phosphodiester bonds. 
Nucleases degrade nucleic acid by breaking either one of these two bonds: (a) First, an enzyme 
residue in the active site deprotonates a water molecule, which can then perform a nucleophilic attack 
in-line from the 5' side breaks the 3'O-P bond and produces 5'-P042' and 3'-OH. (b) Alternatively, a 
nucleophile attacking the scissile phosphate from the 3 'side breaks the 5 'O-P bond and produces 3 '- 
P042' and 5'-OH (Yang 2011).
Nucleases can be protein or RNA and use water, ribose, inorganic phosphate, or the 
side chains of Ser, Tyr or His as a nucleophile. Catalysis may or may not require metal ions. 
The 2 'OH of RNA or free ribonucleotides are additional nucleophiles utilized by RNases.
The pancreatic digestive enzyme responsible for breakdown of RNA, RNase A is a primary 
example for proposed cleavage of a phosphodiester linkage in the substrate chain that occurs 
in two steps (Figure 3). The 2 'OH adjacent to a scissile phosphate often serves as the 
nucleophile and leads to the formation of a labile 2', 3 '-cyclic phosphate (Figure 3a), which 
is then hydrolyzed to produce a 3'-phosphomonoester and a free 5 '-hydroxyl as exemplified 
by RNase A (Figure 3b) (Raines 1998; Usher et al. 1970). His-12 abstracts a proton from the 
T  -hydroxyl of ribose, allowing attack on the phosphoryl group. His-119 acts by protonating 
the leaving 5'-oxygen (Thompson and Raines 1994). Lys-41 stabilizes the excess negative 
charge that develops on non-bridging phosphoryl oxygen during catalysis, donating a 
hydrogen bond to the transition state (Messmore et al. 1995). Raines (1998) had proposed 
the mechanism of RNA hydrolysis by RNase A as proceeding in one two-step process as 
shown in Figure 3, rather than in two one-step processes (Cuchillo et al. 1993; Thompson et 
al. 1994).
10
CHAPTER 1 -  BACKGROUND
A r
BHBf
y m * /  oh
y RNA OH
B
*• r,RNA—^ _ tease
0«i»-0
V h
:b
Figure 3. Schematic diagram for the two step mechanism of the (A) transphosphorylation reaction 
and (B) the hydrolysis reaction catalyzed by RNase A (Findlay et al. 1961; Raines 1998). In both 
mechanism, “B” is His 12 and “A” is Hisl 19.
A number of currently available and successfully used technologies for degrading 
RNA, such as small interfering RNA (siRNA) utilize endonucleolytic cleavage mechanisms 
(Tafech et al. 2006). Dicer and Ago2 are involved in the biogenesis of small RNAs, 
including siRNAs and miRNAs for post-transcriptional gene silencing (Kim et al. 2009; Liu 
et al. 2004). Dicer is responsible for cleaving double-stranded RNAs in which its product 
gets loaded onto the RISC complex and processed by Ago2; thus, they play an important role 
in gene regulation via RNA interference mechanism (Murchison et al. 2007; Liu et al. 2004). 
Gene silencing in the process of RNA interference is mediated by an endoribonucleolytic 
RISC complex. The molecular mechanism of target RNA cleavage of substrates as short as 
15 nt by RISC from human cells proceeds via hydrolysis and releases a 3 'hydroxyl group and 
a 5'phosphate terminus (Figure 4) (Martinez et al. 2009). Product release and/or a 
conformational change rather than the rate of chemical cleavage is limiting for catalysis by 
minimal RISC. The cleavage mechanism of RISC shares molecular features characteristic of 
dsDNA restriction enzymes (Pingoud and Jeltsch 2001) and RNase III enzymes (Dunn 1982), 
and is unrelated to conventional RNase A-type endonucleases that cleave via 2', 3 '-cyclic 
phosphate intermediates and leave a hydrolyzed 3'phosphomonoester (Usher et al. 1970).
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Figure 4. Mechanism of RNA interference. dsRNA are cleaved by Dicer into fragments of 21 nt 
with two-nucleotide 3'overhangs. These siRNAs are incorporated into RISC and unwound. The 
antisense strand guides the activated RISC complex to the target mRNA Cleavage of the mRNA is 
performed by an endoribonuclease, the mRNA fragments with 3'OH and 3'P042' terminus are then 
exoribonucleolytically digested (Cameiro et al. 2011).
1.5 Multifunctional Apurinic/apyrimidinic Endonuclease I (APE1)
APE1 is responsible for 95% of the DNA endonuclease activity in the mammalian 
cell and plays a critical part in the base excision repair (BER) pathway (Chou et al. 2002).
The 35 kDa human APE1 enzyme is a multifunctional protein that is found in the nucleus, 
cytoplasm and mitochondria (Evans et al. 2000; Tell et al. 2005; Chattopadhyay et al. 2006). 
Its known functions in the cell include: endonuclease activity on abasic DNA (AP-DNA), 3'- 
DNA phosphodiesterase activity, 3'-5' exonuclease activity of duplex DNA,, the ability to 
degrade the RNA strand of an RNA-DNA hybrid complex (RNase H activity), and redox 
activation of transcription factors that are implicated in apoptosis and cell growth (AP-1, Egr- 
1, NF-kappaB, p53, and HIF) (Chou et al. 2003; Parsons and Dianova 2004; Tell et al. 2005; 
Kim et al. 2010). Two independent studies provided experimental data in support of APE1 
in RNA metabolism (i) abasic RNA incision activity (Berquist et al. 2008) and its role in
12
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rRNA control (Vascotto et al. 2009), and (ii) the discovery of endoribonuclease activity of 
APE1 and its role in the control of mRNA (Barnes et al. 2009; Kim et al. 2011).
1.5.1 Abasic RNA (AP-RNA) Cleavage Activity
For the first time, Berquist et al. (2008) showed that human APE1 can 
endonucleolytically cleave abasic single-stranded RNA which may represent a potential 
damaged cellular AP-RNA molecule. Thus, APE1 is a potential candidate enzyme that 
cleaves damaged abasic-site-containing ribosomal RNA (rRNA) and transfer RNA (tRNA) 
molecules which pose hindrance to normal protein synthesis (Korennykh et al. 2007). APE1 
was recently shown to interact with rRNA and NPM1, which is a nuclear protein involved in 
a variety of cellular processes including ribosome biogenesis. It was also demonstrated that 
APEl-knocked-down cells were unable to remove 8 -OHG rRNA upon oxidative stress, 
suggesting a possible role for APE1 in RNA quality control (Vascotto et al. 2009).
1.5.2 Endoribonuclease Activity of APE1
In light of the emerging important roles endoribonucleases played in controlling 
specific mRNA transcripts, the endonucleolytic cleavage of mRNAs, as opposed to decay 
from the 3 'and 5' ends, is expected to play a larger role in mRNA metabolism than has been 
traditionally predicted. Barnes et al. (2009) had demonstrated that APE1 has 
endoribonuclease activity that preferentially cleaves c-myc CRD region RNA at single 
stranded UA, CA and UG dinucleotides in vitro. It can also regulate c-myc mRNA levels and 
half-life, suggesting that it may also act as an endoribonuclease in cells (Barnes et al. 2009). 
Furthermore, APE1 has been demonstrated to interact with an RNA-binding protein, hnRNP- 
L (Mitra et al. 2007), and has been co-purified with several others including HADHSC and 
Annexin HI (Barnes et al. 2009). Such interaction with RNA binding proteins, coupled with 
its newly discovered general RNA cleaving activity, suggest that APE1 may play a general 
role in the regulation of the stability of more than one type of mRNA molecules. Recently, 
Kim et al. (2011) showed that the amino acid residues (H309 and E96) critical for its 
endoribonuclease activity are similar to the essential residues for abasic DNA endonuclease 
activity (Barnes et al.2009; Barzilay et al. 1995). This implied a shared catalytic site between 
the DNA and RNA cleaving activities of APE1. However, some biochemical differences
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have been observed for cleaving RNA, abasic single-stranded RNA and abasic DNA by 
APE1 (Kim et al. 2011; Kim et al. 2010). The cleaving mechanism of APE1 for RNA is 
identified as using 2' carbon OH group on the sugar ring in catalysis (Kim et al. 2011), 
whereas DNA has no OH group on the 2' carbon position, and thus, this mechanism of 
catalysis is impossible for DNA.
1.5.3 Human Population Variants of APE1
Involvement of DNA repair genes such as APE1 along with environmental exposures 
has paved the way to identify polymorphic variants that have the potential to cause cancer 
risk (Wilson et al. 2007; Wilson et al. 2011). Polymorphisms in APE1 (164T and 
P31 IS) result in conformational change of the protein, which in turn affects regular 
interaction with DNA (Doss et al. 2012). Altered protein function causes deficit in repair 
capacity, which may lead to genetic instability and carcinogenesis (Yu et al. 2010; Goode et 
al. 2002; Weiss et al. 2005; Synowiec et al. 2008). Single nucleotide polymorphisms (SNPs) 
are the most common and simplest form of human genetic variants. It was estimated that ~ 
90% of human genetic variations are caused by SNPs (Collins et al. 1998). For example, 
changes to amino acids in proteins, such as non-synonymous SNPs (nsSNPs) in the gene 
coding regions, might change the physicochemical property of a wild type amino acid that 
affects the protein stability and dynamics, disrupts the interacting interface, and prevents the 
protein to form a complex with its partners (Collins et al. 1998; Yue et al. 2006; Stitziel et al. 
2004; Uzun et al. 2007).
The C-terminal domain of APE1 is essential for DNA repair activity, while its N- 
terminal domain possesses redox regulatory activity and also contains a nuclear localisation 
sequence (NLS). Evolutionary conservation of APE1 function across different species 
requires at least 10 evolutionarily conserved amino acids (Asp70, Asp90, Glu96, Tyrl71, 
Asp210, Asn212, Asp219, Asp283, Asp308 and His309) in carrying out abasic DNA incision 
(Tell et al. 2005). Known APE1 variants (L104R, PI 12L, E126D, D148E, R237A/C,
G241R, D283G, G306A, P31 IS, T313A and A317V) were found to be located in the 
nuclease domain of APE1 at the C-terminal domain of the protein (Wilson et al. 2011); 
whereas K35Q, G39E, Q51H, G57A, I64V/T are located in the redox domain (Figure 5) 
(Izumi et al. 2005). Within the active site, highly conserved His309 and Thr283 are vital for
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catalytic activity. His309 is believed to act as a general base to abstract a proton from water, 
forming a hydroxide which attacks the scissile bond of the phosphate group 5' to the abasic 
site (Gorman et al. 1997; Lipton et al. 2008).
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Figure 5. Schematic representation of APE1 protein with known APE1 population variants relative 
to the known functional domains of APE1 (Wilson et al. 2011).
In the past, population variant studies on APE1 have focused on the effects of the 
variants on the AP-DNA endonuclease activity. In total, four of seven substitutions in the 
repair domain of APE1 showed reduced function. Particularly L104R, E126D, and R237A 
were found to exhibit -40-60% reductions in overall abasic DNA endonuclease activity as 
compared to the wild-type APE1; A fourth variant D283G/A was found to exhibit —10% 
repair activity (Hadi et al. 2000). Conversely, Kim et al. (2012) recently showed that 
D148E, G241R, R237A, and G306A, exhibited 76-85% reductions in endoribonuclease 
activity against a specific coding region of c-myc RNA. Interestingly, both L104R and 
E126D variants exhibited loss of endoribonuclease cleavage sites and gained additional 
unique cleavage sites, as compared to the cleavage sites of WT-APE1 (Kim et al. 2011). 
Q51H and I64V are located in the redox domain of APE1 therefore they may not have any 
effect on nuclease functions of APE1 (Izumi et al. 2005). Hence, both APE1 variants were 
not characterized by Hadi et al. (2000), but were included in the RNA incision activity tests
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done by Kim et al. (2009). Substitution of any of these residues results in varying degrees of 
reduction in AP-DNA and RNA nuclease activity, and these findings are summarized in 
Table 2, along with the human APE1 population variants and their associations with disease.
Table 2: APE1 human population variants and their associations with diseases: Comparing 
their AP-DNA and endoribonuclease activities
Variant APE1 
Proteins
AP-DNA 
Endonuclease 
Activity relative to 
WT-APE11
Endoribonuclease 
Activity relative to 
WT-APE12
Possible Association with 
Disease
D148E Same as WT-APE1 -23% reduction
• Implicated in many types of 
cancers:
• Bladder (Narter et al. 2008).
• Colon (Pardini, and Kasahara 
2008, Canbay et al. 2011).
• Lung (Shen et al. 2005; 
Agachan et al. 2009).
• Skin (Breton et al. 2007).
L104R ~40-60% reduction in 
cleavage activity
Retained -40% 
incision activity; 
addition of novel 
cleavage sites
• Amyotrophic Lateral Sclerosis 
(ALS) (Olkowski et al. 1998).
E126D -40-60% reduction in 
cleavage activity
Retained -60% 
incision activity; 
addition of novel 
cleavage sites
• ALS (Olkowski et al. 1998).
G241R Slightly enhance 
cleavage activity
-24% reduction • ALS (Hadi et al. 2000).
R237A -40-60% reduction in 
cleavage activity
- 6 % reduction
• R237C APE1 substitution 
with endometrial cancer (Hadi 
etal. 2 0 0 0 )
• Observed in NCBI GenBank 
database
G306A Same as WT-APE1 
(Hadi et al. 2000)
- 2 0 % reduction • ALS (Olkowski et al. 1998).• Observed in NCBI GenBank 
database
I64V N/A -16% reduction
• Decrease risk of lung cancer 
(Zeinolddiny et al. 2006)
• Increase risk in lung cancer in 
association with vinyl chloride 
monomer (Wen-Bin et al. 
2009)
Q51H N/A -23% reduction • Decreased risk of colorectal adenoma (Sonja et al. 2007)
'Taken from Hadi et al (2000); ^aken from Kim etal (2009)
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An amino acid substitution may both affect a specific catalytic function, as well as 
impact interactions with other BER pathway partners leading to a more overall reduction in 
repair efficiency. For instance, D148E, G241R and G306A showed no defect in abasic DNA 
incision activity; however the reduction in RNA incision activity suggests that there may be a 
reduced ability to communicate with other BER proteins giving rise to a reduced BER 
efficiency and thus a potential link to disease susceptibility (Hadi et al. 2000; Kim et al. 
2009). Further studies on APE1 variants in an effort to discover their effects on protein 
structure, nuclease activities, and redox (REF-1) regulatory function should be undertaken to 
gain a better understanding of the association of APE1 polymorphisms and disease.
1.6 Research Objectives
Given the lack of mammalian endoribonucleases identified and characterized to date, 
the identification of a DNA-repair protein such as APE1 is of paramount importance for 
advancing our knowledge about catalytic proteins that function to degrade mRNA. There is 
increasing evidence that APE1 participates in some aspect of RNA quality control, both as 
regulator of c-myc gene expression through mRNA decay and as a “cleansing” enzyme to 
maintain a functional RNome (Berquist et al. 2008; Barnes et al. 2009; Vascotto et al. 2009; 
Kim et al. 2009 and 2011; Tell et al. 2010). In order to further understand APE1 and its role 
in RNA metabolism, the following research objectives were undertaken.
The first objective of my project was to determine if APE1 possesses the 3' RNA 
phosphodiesterase and 3'-5' exoribonuclease activities. To accomplish this, we assessed 
seven RNA substrates (Oligo LA, Oligo IA-RNA, Oligo LA-4 RNA, poly-oligonucleotides 
(A/U/G/Cjis) with different primary and secondary structures and sequences. The 
experiments were performed using RNA sequencing gels to identify the sites and RNA 
structures that were preferentially cleaved by APE1.
The second objective was to determine the critical amino acids responsible for the 3' 
RNA phosphodiesterase activity. To accomplish this, we assessed the RNA cleaving 
activities of previously generated active site mutants of APE1 used in understanding the 
abasic DNA endonuclease and RNA incision activities. Also, using Oligo 1A-4 RNA as 
substrate, we intended to assess the RNA cleaving activities of mutants of APE1 found in
17
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human population and compare them to the abasic DNA endonuclease and RNA incision 
activities. This was expected to give us a better understanding in correlating some of these 
mutants and their aberrant RNA-cleaving activities with human diseases.
The third objective was to assess known inhibitors of APE1 functions on 3' RNA 
phosphodiesterase activity. To better understand the role of 3 ' RNA phosphodiesterase 
activity of APE1 in cells, we first proceeded in finding inhibitors for 3' RNA 
phosphodiesterase activity of APE1. The experiments were performed using RNA 
sequencing gels using Oligo IA-4 RNA as substrate.
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CHAPTER 2
Investigation of 3' RNA phosphodiesterase and 3' exoribonuclease activities of APE1
2.1 Introduction
This chapter presents the methods and discusses the results of experiments conducted 
to determine if APE1 possesses 3' RNA phosphodiesterase and 3 'exoribonucleolytic 
activities. Various single-stranded RNA sequences were tested.
Studies thus far have demonstrated that recombinant APE1 possesses 
endoribonucleolytic activity that cleaves the single stranded regions or weakly base-paired 
regions of RNA. The preferred cleavage sites were determined to be UA, UG, and CA 
dinucleotides (Barnes et al. 2009). APE1 was also reported to preferentially hydrolyze RNA 
structures that are more flexible and structures where the bases are more likely to interact 
with RNA binding proteins and enzymes. (Kim et al. 2009). In this study further 
investigation was done to demonstrate APE1 3 'RNA incision activity on 17nt RNA substrate 
Oligo 1B, with sequences corresponding to the c-myc CRD region of 1741 -1757. The 
objective of this chapter was to confirm the 3 'phosphodiesterase and 3 'exoribonuclease 
activities of APE1 on modified 3 2P-labeled Oligo IB RNA substrates using time course and 
different protein concentration electrophoretic assays.
2.2 Materials and Methods
This section describes the methods used in investigating the possible presence of 
3'RNA phosphodiesterase and 3'-5'exoribonuclease activities of APE1 on modified 3 2P- 
labeled Oligo IB RNA substrates and unstructured RNAs (Table 3).
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Table 3: List of RNA substrates and their primary sequences. All the oligos were 
commercially synthesized from IDT, San Diego, CA. rU, rA, and rG indicate the ribose 
moieties linked to the Uridine, Adenine, and Guanine bases.
RNA Substrate Oligonucleotide sequence
Oligo-IA 5 ’-C AAGGT AGT rU AG ATCCTTG-3 ’
Oligo-IA-RNA 5 ’-iCrArArGrGrUrArGrUrUrArUrCrCrUrUrG-3 ’
Oligo-IA-4R 5 ’ -C AAGGGrArGrGrU ATCCTT G-3 ’
AlSOligo 5 ’ -rArArArArArArArArArArArArArArAr- 3 ’
U15-Oligo 5 ’-rUrUrUrUrUrUrUrUrUrUrUrUrUrUrU-3 ’
G15-Oligo 5 ’-rGrGrGrGiGrGrGrGrGrGrGrGrGrGrG-3 ’
C15-Oligo 5 ’ -rCrCrCrCrCrCrCrCrCrCrCrCrCrCrC-3 ’
T .JO nt
G T rU G u  U ‘ rG rG r lT "
A A A A rA A
T T U U T T
Sot- S o . - - G ~  C .  .  - G -----CSot—
G ----- C G ------C G -----C
A ----- T > 1 c A -----T
A ----- T A ------ U A -----T
5’C —  S ’ 5-C — G 3’ 5-C — G 3-
OIA B) OIA-R C ) OIA-4R
Figure 6. Secondary structures of substrates: (A) 01igoIA_ 17nt (OIA), (B) 01igoIA-RNA_17nt 
(OIA-R), and (C) 01igoIA-4RNA_17nt (OIA-4R). These structures were created by Mfold RNA 
folding program (http://frontend.bioinfo.rpi.edu/applications/mfold.
2.2.1 Reagents and buffer preparation
The reagents listed in Table 4 were used through-out this study.
Table 4: Reagents name and composition utilized during the 5 '-radiolabelling procedure.
Reagent Composition
lOx Glycogen 0.2 mg/mL Glycogen, 3 M sodium acetate pH 5.2
lOx Alkali Buffer 500 mM sodium bicarbonate pH 9.2 and 10 mM EDTA
RNA stop dye 9M Urea, 0.01% bromophenol blue, and 0.01% xylene cyanole FF
SVP buffer 99 mM Tris, 14 mM MgCl2, and 100 mM NaCl
0.5x TBE 0.45 M Tris-HCl/Boric acid (Sigma) pH 8.3, 5 mM EDTA
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2.2.2 Dephosphorylation of RNA substrates
All the oligos mentioned in Table 3 were individually dephosphorylated at the 5' end 
under similar conditions. The substrates were incubated in 37°C for 1 hour with a final 
concentration of 768 pmol/pL. The 80 pL reaction mixture contained 40 U/ pL RNasin®
Plus RNase Inhibitor (Promega, Madison, WI), 2 U/ pL Calf Intestine Phosphatase/CIP (New 
England Biolabs, Beverly, MA), 1 x NEB Buffer 3 (New England Biolabs, Beverly, MA), 10 
nM DTT (Promega, Madison, WI). The rest of the volume was adjusted with autoclaved 
water. The reaction was stopped by adding 20% SDS, 5 M NaCl, 0.5 M EDTA (8.0 pH), and 
autoclaved water. Following the dephosphorylation, substrates were subjected to standard 
phenol/chloroform extraction.
2.2.3 Standard phenol/chloroform extraction and ethanol precipitation
Autoclaved water was added to bring the volume of RNA sample to 200 pL. Vi 
volume of phenol (100 pL, pH 6.7, Sigma) and lA volume of chloroform:isoamylalcohol 
(CHCl3 :IAA = 4:1, Fluka) were added to the sample and mixed by gentle inverting. The 
mixture was then centrifuged at 12,000 rpm for 5 minutes at 4°C. The aqueous layer was 
transferred to a new tube, then an equal volume of chloroform: isoamylalcohol (CHC13:IAA = 
57 4:1, Fluka) was added to it and mixed by gentle inverting. The mixture was centrifuged at
12.000 rpm for 5 minutes. The aqueous layer was then transferred to new tube, then 2 
volumes of 100% ethanol and 1/10 volume of lOx Glycogen (pH 5.2) were added to it. The 
tube was mixed well and put in -20°C for at least 30 minutes. The RNA was precipitated out 
by spinning the tube at 12,000 rpm for 10 minutes. The supernatant was gently pipetted out 
ffom the tube. The pellet was rinsed by adding 200 pL of 70% ethanol and spun down at
12.000 rpm for another 5 minutes. After gently pipeting the ethanol from the tube the pellet 
was dried in the fume hood for 20 minutes, and then the pellet was re-suspended with 20 pL 
of autoclaved water. The concentrations of all the extracted RNA were individually 
measured by adding 2uL of the sample to NanoDrop® (Thermo Scientific) and further 
diluted to give a final concentration of 6  pmol/pL.
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2.2.4 Generation of 5 radiolabeled RNA substrates
A 15 pL reaction mixture containing 6  pL dephosphorylated RNA ( 6  pmol/pL), 1.25 
pL 10 x PNK buffer, 1.5 pL of 1U/ pL T4 PNK, 1 pL of 40 U/ pL RNasin® Plus RNase 
Inhibitor (Promega, Madison, WI), 1 pL of 100 mM DTT (100 mM) (Promega, Madison, 
WI), 3.0 pL y-3 2P-ATP (10 pCi/ pL/3.32 pmol, PerkinElmer Inc., Waltham, MA) and 1.25 
pL autoclaved water was added together and incubated at 37°C for 1 hour. The reaction was 
stopped by adding 18 pL stop dye in each tube. Labelled substrates were immediately 
subjected to gel purification using 15% denaturing PAGE.
Gel Purification
The 15% denaturing polyacrylamide gel consisted of 48 ml pre-made 15% acrylamide 
containing 7M urea with 65 pL of TEMED (N,N,N',N'-tetramethylethylenediamine) and 180 
pL 20% APS. Once the 5'-labelled substrate was fully loaded into the wells of 15% 
denaturing polyacrylamide gel, the full length substrate was separated from degraded 3 2P- 
labeled RNA and excess free y-32P-ATP by running at 25 mAmp for an hour. The intact 
substrate was sliced out directly from the gel. The gel slice was then put into an RNase 
DNase free sterile eppendorf tube and ground using a sterile pestle into fine pieces. The 
substrate was eluted out of the ground gel slice by adding 200 pL autoclaved water to the 
tube, and the mixture was then transferred directly to a prepared PERFORM A® DTR (Dye 
Terminator Removal) Gel Filtration Cartridge (EdgeBio). The DTR columns were prepared 
by spinning the storage buffer in the column for 3 minutes at 850x g. To avoid break down of 
sensitive substrate, incubation under high temperature was eliminated from the instructed 
DTR gel filtration cartridge protocol. After loaded with ground gel mixture, the DTR gel 
filtration cartridge was spun down at 850x g for 3 minutes and the eluted substrate was 
collected in a new 1.5 mL eppendorf tube. The eluted substrate was then further subjected to 
phenol-chloroform precipitation. Dried radiolabeled RNA pellet was re-suspended by adding 
30 pL autoclaved water. Then 1 pL of labelled RNA sample was subjected to scintillation 
counting in-order to give a final count of approximately 100,000 CPM/pL before carrying 
out the reaction.
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2.2.5 Assessing the Phosphodiesterase and Exoribonucleolytic activity of APE1
For each reaction, 2 pL of 5 '-labelled substrate (100,000 CPM) was incubated at 
37°C in 18 pL reaction buffer containing 0.2 pL of 1M Tris (pH 7.4), 0.4 pL of 100 mM 
DTT, 0.4 pL of 100 mM MgOAc and autoclaved water, which was made freshly prior to 
proceeding to the reaction, and designated amount of protein (e.g., 0.5 or 1 pg). The typical 
incubation time for a concentration dependent experiment was between 10-60 minutes.
2.2.6 Determination of RNA cleavage products
Two types of negative control were incorporated in every set of experiments (Input 
and None). Input negative control was prepared by adding 2 pL of labelled substrate 
(100,000 CPM) with 40 pL RNA stop dye; the None negative controls differed from Input by 
addition of 18 pL of reaction buffer. There was no incubation required for Input, while the 
None had a different incubation time that matches up with the protein samples. In 
concentration dependent experiment, negative control reactions were typically incubated for 
0  and 30 minutes respectively.
To determine the potential cleavage of the substrates, three markers were run in 
parallel (alkaline hydrolysis ladder, RNase A and RNase Tl). The alkali ladder was made by 
incubating 5 pL of labelled substrate (100,000 CPM) with 1 pL of lOx alkali buffer and 4 pL 
autoclaved water at 95°C for 3 minutes, and then on ice for 1 minute before putting 20 pL of 
RNA stop dye. RNase A ladder was produced by incubating labelled substrate (100,000 
CPM) with 1 pL lOx Structure buffer (Ambion, Austin, TX), active RNase A (0.025ng/ pL, 
Ambion, Austin, TX) and autoclaved water at room temperature for 30 minutes. RNase Tl 
ladder was prepared by incubating labelled substrate (100,000 CPM) with 3 pL of active 
RNase Tl (Roche Diagnostics Inc, Mannheim, Gemany) and 4 pL of lx Sequence buffer 
(Ambion, Austin, TX) at room temperature for 5 minutes.
Snake Venom Phosphatase (SVP) reactions are included as positive controls. 
Reactions with two incubation periods of 2 and 5 minutes were performed by mixing SVP 
(3x 10-5 units, Sigma, St. Louis, MO) with 12 pL SVP buffer (99 mM Tris, 14 mM MgCh, 
100 mM NaCl) in the presence of labelled linear poly-ribonucleotide (100,000 CPM). 
Reaction was stopped by adding 40 pL of RNA stop dye.
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2.2.7 Sample loading and gel running
All reactions, except for the alkali hydrolysis digestion, typically ranged between
80,000 to 100,000 CPM. Since not all reactions had the same volume, the CPM per pL 
concentrations varied. It was important to have the same radioactivity in all lanes to visualize 
and compare the reactions at different time points or with different protein amount. Since the 
purpose of including the markers (Alkali ladder, RNase Tl and RNase A reactions) was to 
assign the nucleotide position, the CPM count was not critical to their enzymatic function.
The CPM counts of all lanes loaded in the 15% polyacrylamide gel, except for the markers, 
were normalized by adjusting the sample volumes loaded to the well.
After loading samples to each well, the gel was run at 15 mAmp for 90 minutes in
0.5x TBE buffer. The gel was put in a -80°C freezer on one glass plate exposed to a Phosphor 
Screen (Packard, Meriden, CT). Exposure was typically done over night in the freezer. On 
the following day, an image of the gel was taken using the Cyclone Phosphor Imager 
(PerkinElmer, Waltham, MA) with OptiQuant software (Hewlett Packard, Palo Alto, CA). 
Post editing of the images was done using CorelDRAW software (Corel, Ottawa, ON).
2.3 Results
2.3.1 Generation of unlabeled and 5 '-radiolabeled RNA
Commercially obtained RNA oligonucleotides (Table 3) were radiolabeled and then 
subjected to purification by excision and elution. The size of the radiolabeled RNA was 
estimated using the internal standards xylene cyanol and bromophenol blue. For example, 
shown in Figure 7 are the 5'-radiolabeled OligolA RNA, and Poly-Oligo (A) 15 RNA.
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Figure 7. Polyacrylamide gel analyses of 5'-radiolabeled RNA substrates. 15% polyacrylamide 
denaturing gel shows Oligo 1A RNA that had been 5'-end radiolabeled with y-32P-ATP using T4 
polynucleotide kinase (left). On the right, 15% polyacrylamide denaturing gel shows Poly-Oligo (A) ]5  
RNA substrate that had been 5'-radiolabeled in the same manner as the Oligo 1A RNA
2.3.2 APE1 Possesses 3 'RNA Phosphodiesterase and 3'-5 ' Exoribonucleolytic 
Activities
We investigated whether APE1 is able to generate 3'RNA decay products with 
3'hydroxyl or 3'phosphate groups to further highlight the role of APE1 in degrading RNA. 
Generation of a 3 'hydroxyl group would indicate that APE1 has 3 'phosphodiesterase activity 
(Yang 2 0 1 1 ); and further nucleotide removal from 3'end by 3'-5'exoribonuclease activity 
would generate nucleotide monophosphates or diphosphates, respectively with 3'phosphate 
groups (Ibrahim et al. 2008).
Kim et al. (2009) indicated the possibility that APE1 may possess another type of 
3'RNA nuclease activity. In their study, recombinant type APE1 (WT APE1) and its variants
25
CHAPTER 2 -  INVESTIGATION OF 3 RNA PHOSPHODIESTERASE AND
3'EXORIBONUCLEASE ACTIVITIES OF APE1
were challenged with 17nt RNA substrate, Oligo IB, that can form a single stem and a 
hairpin structure and has an identical sequence to the c-myc CRD region of 1741-1757 (Kim 
et al 2009). Oligo IB is composed entirely of deoxyribose-phosphate backbone except at 
base position 6 nt, where a Uridine base is bonded to a ribose sugar. In their observations on a 
medium sized 8 % denaturing polyacrylamide gel there was an indication of two cleavage 
products of similar intensities that were generated by WT APE1, D70A, Y171F, D210N, and 
H309S variants. The identity of the 6 nt product was proposed to have resulted from the 
endoribonuclease activity (further discussed in chapter 3.3.1) of APE1 cutting in between 
rUpA dinucleotides whereas the 5nt product was proposed to have resulted from a 3 '-5 ' 
exoribonuclease activity of WT (Kim et al 2009). To this end, this study was then set-up to 
investigate whether APE1 indeed possesses additional 3 'RNA cleaving activities, in this case 
either 3' RNA phosphodiesterase or 3 '-5 ' exoribonuclease activities or both.
To determine whether APE1 possesses 3' phosphodiesterase and 3 '-5' 
exoribonuclease activities, we challenged the enzyme with seven new substrates (Table 3). 
First, we tested APE1 on 5'labeled y-3 2P-ATP Oligo LA RNA to see whether the protein was 
able to generate 3'RNA cleavage products at 10UA and 6 UA sites, as was seen on Oligo IB 
at nucleotide position 6  (Kim et al. 2009). Oligo LA RNA is composed entirely of ribose 
sugars. Fig. 8 A shows the 5 'fragments of the cleavage products generated by different 
concentrations of APE1 (lane 5-9) on the 5'labeled RNA. The secondary structure of 17 nt 
Oligo IA RNA (Figure 8 B) was predicted using M-fold program (Zuker 2003). Using Oligo 
LA RNA as substrate, we observed the following (Figure 8  A and B, lane 5): (i) the lowest 
concentration (0.1 pg) of APE1 generated two 3 'end cleavage products that cut strongly at 
10UA (closer to 3 'end) and weakly at 9 UU (closer to 5 'end), (ii) From 0 .25-1 .0  pg, APE 1 
generated a band in-between 10UA and 9UU, suggesting that this product is 3'OH decay 
product of lOnt UA. (iii) APE1 cut strongly at 6 UA, and weakly at 5GU that became more 
intense as the amount of protein in the reaction was increased from 0 . 1  pg to 1 . 0  pg. (iv) 
Conversely, RNase A does not generate 3'-hydroxyl group RNA cleavage products, thus 
there is no band in-between 10UA and 9UU. However, it does show strong cleavage at 
10UA and 6 UA, weak cleavage at 9UU and 5GU on the ssRNA, which is in accordance with 
the cleavage specificity of RNase A (Barnard 1969; Sorrentino and Libonati 1994).
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Figure 8 . Concentration-dependent effect of APE1 on 5'-labelled Oligo IA RNA_17nt. (A) 
Different amounts (0.1 to 1.0 pg) of APE1 (lanes 5 to 8 ) and 0.25 pM of RNase A (lanes 9 to 12) 
were tested against 5 '-y-32P-ATP radiolabeled Oligo LA RNA (100,000 CPM) in a total reaction 
volume of 20pl for 30 mins at 37°C. (B) The Secondary structure of Oligo LA RNA predicted 
through Mfold is used to indicate the APE1 3 RNA cleavage products at 10 nt UA, 9 nt UU, and 6  nt 
UA.
A time dependent electrophoretic assay (Figure 9 A) was used to confirm whether the 
3'RNA cleavage products generated by APE1 on Oligo IA RNA (Figure 9B) were a 
3 'phosphate or a 3 'hydroxyl group. A snake venom phosphatase (SVP) digestion (Figure 
9A, lane 2) was used to differentiate between the products with 3 'hydroxyl versus products 
bearing 3'phosphate groups (Chemokalskaya et al. 1997; Schoenberg and Cunningham, 
1999). RNase A (lanes 10 to 12) was used as a marker to designate products with 
3'phosphates at unpaired U residues (delCardayre et al. 1995). The cleavage pattern 
generated at the base position U by APE1 on Oligo LA RNA and other RNA substrates tested 
are similar but not identical to that generated by RNase A. The 3 'RNA phosphodiesterase
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cleavage products, however, provided evidence that support the argument against the 
possibility that the observed nuclease activities of APE1 are due to RNase A contaminants.
Foremost, in Figure 9A at reaction time of 30 mins (lane 7), the identity of the 6 nt 
product (Figure 9E) seemed to have resulted from the known RNA incision activity of APE1 
cutting in between UA dinucleotides; whereas the complete removal of the Uracil base 
located at 5nt may have resulted from 3' exoribonuclease activity of APE1 that is not clearly 
evident in the RNase A cleavage products (lane 9-12) (Chen et al. 1991; Kim et al. 2009).
The weak 5nt cleavage product generated by WT APE1 (lane 7 and 8 ) suggested that the WT 
can slightly remove rU that hangs on to the recessed strand of the RNA structure relative to 
increase in time (Figure 10). Kim et al. (2009) had done a related analysis focused on the 
DNA structure, Oligo IB that had also generated a similar rU cleavage product at 5nt site. 
These results supported the notion that APE1 possesses 3 'exoribonuclease activity.
The identity of the cleavage product (Figure 9C) at 10UA (closer to 3 'end) resulted 
from the known 3'RNA endoribonuclease activity of APE1 that cut strongly in between the 
UpA dinucleotides generating a product with a 3 'phosphate group; whereas the 1 Ont product 
(closer to the 5 'end) resulted from the removal of a 3 'phosphate group from the 
endonucleolytic decay product, thus leaving a cleavage product with a 3 'hydroxyl group that 
is parallel to the 3'RNA decay products generated by SVP (lane 2). This band was not 
observed in samples treated with RNase A (lanes 9 to 12) which does not have 
3'phosphodiesterase activity. Unlike RNase A, APE1 has an additional ribonuclease activity,
i.e., 3'phosphodiesterase activity as demonstrated against Oligo IA RNA substrate in dose- 
and time-dependent experiments. This is further supported in experiments where Oligo IA 
and Oligo IA-4 R were used (Figure 12). These results further confirm the distinct 
ribonuclease activities of APE1 and RNase A. An enzyme kinetic analysis (Figure 11) 
indicates a transition between the dephosphorylation of the endoribonucleolytic cleavage 
product with a 3'phosphate group to a 3 'RNA phosphodiesterase cleavage product with a 
3'hydroxyl group relative to increase with reaction time. One noteworthy observation was 
that following the endoribonucleolytic and 3 'RNA phosphodiesterase activity between the 
UAlOnt site on Oligo LA-RNA there were two other cleavage products of weaker intensities 
that were generated between the UU dinucleotides located at the 9nt site (Figure 9D). The
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observed 9nt cleavage product seems to have resulted from another APE1 3' 
endoribonucleolytic incision between the UU dinucleotides that is also evident in RNase A; 
whereas the second cleavage product between the UU dinucleotides corresponds with SVP 
that seems to have resulted from the 3 'RNA phosphodiesterase activity of APE1. To further
• 32confirm the presence of 3 'phosphodiesterase activity we assessed APE1 on different P- 
Oligo RNA substrates that are mentioned in section 2.3.3. Also the 3'-5' exoribonuclease 
activity of APE1 is further investigated on linear substrates in section 2.3.4.
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Figure 9. Time-dependent effect of APE1 on 5 '-labelled Oligo IA RNA_17nt. (A) 0.1 pg of APE1 
(lanes 6  to 8 ) and 0.25 pM of RNase A (lanes 9 to 11) were tested against 5 '-y-32P-ATP radiolabeled 
Oligo IA RNA (100,000 CPM) in a total reaction volume of 20 pi at the increasing time points. (B) 
Structure and sequence of the Oligo LA-RNA and its incised products between the dinucleotides: (C) 
10 nt UA (D) 9 nt UU, (E) 6 nt UA
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Figure 10. Kinetic analysis of APE1 towards 5’-labeled Oligo IA RNA. The relative increase of 
radioactivity was indicated by the band intensity for both the 6 nt endoribonucleolytic and 5nt 3'- 
5'exoribonucleolytic cleavage products. The intensity of band was measured using OptiQuant 
Software. The increase of band intensity was calculated by using the band intensity at a particular 
time point against the intensity of a randomly selected background. Results presented represent 
averaged data ± standard deviation from three independent experiments.
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Figure 11. Kinetic analysis of APE1 towards 5’-labeled Oligo IA RNA The relative radioactivity 
was indicated by the band intensity of 3' phosphodiesterase product (10UA) and increase of band 
intensity of 3' hydroxyl product (10UA) cleavage sites. The intensity of band was measured using 
OptiQuant Software. The increase of band intensity was calculated by using the band intensity at a 
particular time point against the intensity of a randomly selected background. Results presented 
represent averaged data ± standard deviation from three experiments.
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2.3.3 Confirmation of 3' RNA phosphodiesterase activity of APE1 as assessed against 
Oligo IA and Oligo IA-4 RNA
As seen in Oligo IA RNA, two distinct products can be observed between the rUpA 
dinucleotides at lOnt for both the RNA substrates Oligo IA and Oligo IA-4RNA when tested 
with 0.1 pg of APE1 (Figure 12A and 12B, respectively). Oligo IA is composed entirely of 
deoxyribose-phosphate backbone except at base position 1 0 , where a uracil base is bonded to 
a ribose sugar; and Oligo IA-4 RNA is also composed entirely of deoxyribose-phosphate 
backbone except at base positions 7-10, where an adenine, two guanines, and a uracil base 
are bonded to ribose sugars, respectively. APE1 endonucleolytically cleaved Oligo IA and 
Oligo IA-4RNA generating decay products with a 3 'phosphate group that is in accordance 
with the known 3 'RNA incision activity of APE1. APE1 appears to have weaker 
endoribonucleolytic and 3 'RNA phosphodiesterase activities against Oligo IA-RNA and 
Oligo IA as compared to Oligo IA-4RNA. Oligo IA and Oligo IA-4RNA substrates also 
showed a cleavage in between the UAlOnt  dinucleotide followed by the removal of a 
3'phosphate group, leaving decay product with a 3'hydroxyl group that correspond with the 
3'hydroxyl group cleavage product generated by SVP (Figure 12A, lane 13). Considering all 
the stem-looped structured substrates that were tested consisted of rUA at base position lOnt 
this suggests that APE1 possesses 3'endoribonuclease activity, followed by removal of 
3 'phosphate group between the UA site that generate a product with a 3 'hydroxyl group thus 
confirming the presence of 3 'RNA phosphodiesterase activity. Judging from the identical 
cleavage sites generated at the 10UA by APE1, and the specific fragments generated by 
APE1 on other RNAs, we conclude that the 3 RNA phosphodiesterase activity of APE1 is 
not substrate-specific but rather sequence-selective. Unlike RNase A, APE1 exhibited ability 
to remove a single rU at position 6 nt of Oligo IA RNA (Figure 9) substrate demonstrating its 
3 'exoribonuclease capability. However its 3 'exoribonuclease activity appears to possibly be 
structure specific because we did not see this activity on Oligo IA and Oligo IA-4 RNA 
substrates (Figure 12).
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Figure 12. Concentration-dependent effect of APE1 on 5 '-labelled Oligo I RNA_17nt and Oligo IA- 
4 RNA_17nt. (A) 0.1 pg of APE1 (lanes 5 to 8 ) and 0.25 pM of RNase A (lanes 9 to 12) were tested 
against 5’-y-32P-ATP radiolabeled Oligo I RNA (100,000 CPM) in a total reaction volume of 20 pi 
for various time points (10 to 60 mins) at 37°C. Secondary structure of Oligo I RNA (right) predicted 
through Mfold showing its APE1 RNA 3' phosphodiesterase product (lOnt) and 3' hydroxyl product 
(lOnt) (B) 0.1 pg of APE1 (lanes 5 to 8 ) and RNase A (lanes 9 to 12) were tested against 5'-y-32P- 
ATP radiolabeled Oligo IA-4 RNA (100,000 CPM) in a total reaction volume of 20 pi for various 
time points (10 to 60 mins) at 37°C. Secondary structure of Oligo IA-4 RNA (right) predicted 
through Mfold showing its APE1 RNA endoribonuclease (lOnt) 3'phosphate end product and 
3'phosphodiesterase (lOnt) 3' hydroxyl end product.
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2.3.4 APE1 possesses weak 3'exoribonuclease activity of APE1
To further investigate if APE1 has 3'-5' exoribonucleolytic activity, we first 
challenged recombinant APE1 with 5'radiolabeled Poly (A) I5  RNA substrate (Figure 13). 
Only weak APE1 3 'exoribonuclease activity was detectable 60 minutes after incubation (lane 
4) as compared to the strong cleavage by snake venom protein (SVP) (lane 7 to 9) that 
cleaved Poly A from the 3 'end. Directional exoribonucleolytic cleavage was indicated by the 
laddering patterns of bands at different time points. SVP cleaves from the 3 'end. The 
5 'radiolabeled Poly (A) ! 5  appeared to be degraded from the 3 end in the presence of 0.1 pg 
APE1, and the cleavage products increased in intensity relative to increasing time point from 
10 to 60 mins (lane 5-6). These observations suggested that APE1 exhibits weak 3'-5 ' 
exoribonuclease activity. APE1 was also exhibited weak 3'exoribonuclease activity towards 
Poly (U)is, and Poly (C)is substrates (Figure 14). Poly (G)i5 oligonucleotide was not assessed 
because of the difficulty in synthesizing long stretches of G ribonucleotides. That may have 
been due to the fact that poly-guanosine stretches (with greater than four Gs) have the 
likelihood to form tetraplexes (complexes consisting of four different strands all bound at the 
poly G region) (Bates et al. 2009). These complexes are very tightly linked and make 
oligonucleotide synthesis difficult, and thus the sequence is not recommended for use.
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Figure 13. Time-dependent effect of APE1 on 5'-y-32P-ATP radiolabeled poly-oligo (A)i5 substrate.
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Figure 14. Time-dependent effect of APE1 on 5'-y-32P-ATP radiolabeled (a) poly-oligo (U)i5 
substrate and (b) poly-oligo (C)i5 substrate.
2.4 Discussion
To date, only the endoribonucleolytic activity of human APE1 has been demonstrated 
against RNA substrates. These include: the 182 nt coding region determinant of c-myc 
mRNA (Barnes et al. 2009); Oligo IB substrate, a sequence corresponding to the c-myc CRD 
region of 1741-1757 (Kim et al. 2009); spike, orflb and orf3 RNAs which are derived from 
proteins important for the life cycle of the SARS-corona virus (Kim et al. 2010); and abasic 
RNA (Berquist et al. 2008; Kim et al. 2010)
In this study, the experimental data supports the role of APE1 as an endoribonuclease 
that also has an additional ribonuclease activity, i.e. 3 ' RNA phosphodiesterase activity as 
demonstrated against single-stranded Oligo IA RNA substrate in dose- and time-dependent 
experiments. This was further confirmed in experiments where Oligo IA and Oligo IA-4 
RNA substrates were used. APE1 was consistently shown to cleave endoribonucleolytic at 
1 0 UA dinucleotide generating 3 'P0 4 2‘ group cleavage product, which is directly followed by 
removal of the 3'phosphate group. APE1 also exhibits structure specific exoribonucleolytic 
activity as it removes a single rU at base position 6 nt of Oligo IA RNA substrate. The weak
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3'exoribonuclease activity of APE1 was confirmed on unstructured poly(A)i5 , poly(U)i5 , and 
poly(C) , 5  RNAs.
The fact that APE1 has similar endoribonuclease activity, i.e., preferentially cleaves 
at UA, UG, and CA at single-stranded region had drawn scepticism regarding the possible 
contamination of APE1 (purified native and recombinant protein) preparation with RNase A. 
Here, we clearly demonstrated the distinct ribonuclease activity of both enzymes, i.e., the 
cleavage pattern generated by APE1 on Oligo IA RNA (Figure 9) and other RNAs (Figure 
12) possesses 3 'RNA phosphodiesterase activity but RNase A does not have such activity. 
APE1 has weak 3 'exoribonuclease activity. To our knowledge, this is the first 
demonstration of a single polypeptide enzyme with more than one type of ribonuclease 
activities. For instance, all self-cleaving ribozymes found to date only endonucleolytically 
cleave RNA (Cochrane and Strobel 2008; Lilley et al. 2005). This is unique and suggests 
that RNA substrates (and their decay products) subjected to endonucleolytic cleavage by 
APE1 in cells are unlikely to remain intact.
The major finding here is that in addition to the endoribonucleolytic activity, APE1 
also has 3'RNA phosphodiesterase activity and a 3'exoribonuclease activity which appear to 
be preferential for removal of one nucleotide at 3 'overhang. The results suggest that the 
endoribonuclease activity of APE1 is the composite of at least two component steps: (i) the 
3 '-terminal ribonucleoside is first removed to yield a primer strand with a ribonucleoside 3 '- 
P0 4 2' terminus, and (ii) then the 3 '-PO4 2' is hydrolyzed to a 3 '-OH by the 
3'phosphodiesterase activity of APE1. This sequential mechanism is supported by the 
enzyme kinetic data presented (Figure 11) for a precursor-product relationship of the 3 '-PC>4 2' 
and 3 '-OH strands. During the course of the reaction time (10 — 60 mins) WT-APE1 
converts the endoribonucleolytic 3 '-PO4 2' group cleavage product into the 3 'RNA 
phosphodiesterase 3 '-OH cleavage product. These findings have implications for further 
understanding the role of APE1 in mRNA metabolism and its mechanism of catalysis.
The 3'exoribonuclease activity appears to be similar to APEl’s 3 'exonuclease 
activity against DNA (Suh et al. 1997; Chou et al. 2002 and 2003), i.e., preference in 
removing one nucleotide at 3'overhang. In general, human APE1 has been found to be a non-
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or poorly- processive 3 '-5' exonuclease (Wilson et al. 2003). In terms of substrate 
specificity, human APE1 shows similar affinity (Km ~250 nm) towards 3' termini, but 
varying degrees of turnover (Kcat) in decreasing order for 3' recessed DNA, lnt gapped 
DNA, nicked DNA, and 2nt gapped DNA (Wilson et al. 2003). Activity is not detectable 
towards one base removal on a 3' overhang on duplex DNA or on single-stranded DNA (Suh 
et al. 1997). However, secondary structure can influence incision activity of APE1 on single­
stranded AP-containing oligonucleotides (Fan et al. 2006). Also APE1 can remove 3 - 
mismatched nucleotides at least 50 times more efficiently from nicked DNA than from 
recessed DNA (Chou et al. 2002). The reduced APE1 exonuclease activity seems to arise 
from constraints in the active site residue and/or DNA substrate (Wilson et al. 2003). Other 
than APE1 ’s ability to effectively remove single ribonucleotide at 3'overhang, the 
3'exoribonuclease activity of APE 1 on un-structured polyribonucleases (poly A, poly C, and 
poly U) appeared to be extremely weak suggesting that, in general, APE1 is unlikely to 
function as a regular 3 'exoribonuclease in cells. Furthermore, signifying the catalytic domain 
probably only accommodates single stranded-RNA, explaining the requirement for a 3' linear 
overhang to initiate degradation. Clearly, resolution of APE1 structure by assessing its active 
site residues is the key to fully understanding its remarkable mode of action.
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CHAPTER 3
Identifying the critical amino acid residues responsible for 3' RNA phosphodiesterase 
activity of APE1
3.1 Introduction
Results from Chapter 2 showed that APE1 exhibits its endoribonucleolytic and 
3 phosphodiesterase activities against UA and UG sites of its substrate RNAs. However, the 
responsible active site residues for carrying out the 3'RNA phosphodiesterase cleavage are 
unknown and it is intriguing to assess if these residues are shared with the endoribonuclease 
activity of APE1 (Barnes et al. 2009, Kim et al. 2009). In 2009, researchers in Dr. Lee’s lab 
had assessed a number of recombinant APE1 variants on Oligo IB substrate. Experiments 
were carried out to examine the effect of these APE1 variants on endoribonuclease activity 
(Kim et al. 2010). When challenged with an Oligo IB substrate, I64V, Q51H, N 6 8 A, D70A, 
Y171F, D210N, F266A, D283N, H309S, D148E, R237A, G241R and G306A variants 
showed decreased RNA cleaving activity as compared to that of wild-type APE1 (Kim et al. 
2010 and 2011). The L104R and E126D variants possess altered cleavage sites on the RNA 
substrate as both variants lost the common cleavage sites and gained additional unique 
cleavage sites, respectively, as compared to the cleavage sites of wild-type APE1. 
Interestingly, D70A, Y171F, D210N, and H309S variants had shown two cleavage products 
of similar intensities between the UG dinucleotide at the 6 nt and 5nt site on the substrate 
(Kim et al. 2011). In this study we assessed the aforementioned APE1 variants for 3 'RNA 
phosphodiesterase activity on a modified 3 2P-01igo IB RNA substrate, Oligo 1A-4RNA; then 
determined if there are different or similar amino acid residues involved in endoribonuclease 
and 3 'RNA phosphodiesterase activities of APE 1. As part of a collaborative effort and as in 
previous study (Kim et al. 2009), we obtained all APE1 variants from Dr. David Wilson 
(National Institute on Aging, NIH).
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3.2 Materials and Methods
The methods used are the same as those described in Chapter 2.
3.3 Results
As in Chapter 2, Oligo LA, Oligo LA-RNA and Oligo IA-4RNA substrates (Figure 6) 
were radiolabeled and were subjected to purification by excision and elution. The sizes of the 
32P-y-ATP radiolabeled RNAs were estimated using the internal standards xylene cyanole 
and bromophenol blue. We have previously demonstrated that the specificity of the RNA 
endoribonuclease and 3 'phosphodiesterase activities exhibited by the recombinant wild-type 
APE1 occurred within the single-stranded loop region, between the 10UA and 9UU sites.
The substrate most efficiently processed by both the 3 'RNA incision activities of APE1 was 
Oligo IA-4RNA, between the 10UA site. Oligo LA-4 RNA is a modification of the Oligo IB 
RNA substrate that was used to carry out the assessment of the APE1 variants for 3 'RNA 
phosphodiesterase activity, and also to determine the differences and similarities between the 
amino acid residues involved in endoribonuclease and 3 'RNA phosphodiesterase activities.
3.3.1 Identification of essential residues for 3 'RNA phosphodiesterase activity of 
APE1
APE1 variants, H309S, H309N, D283N, N68A, D308A, D210N, F266A, D70A, and 
Y171F, were challenged with the 17 nt Oligo IA-4 RNA substrate (Figure 15). Oligo LA-4 
RNA is composed entirely of deoxyribose-phosphate backbone except at base positions 7-10, 
where an adenine, two guanines, and a uridine base are bonded to ribose sugars, respectively. 
As shown in Chapter 2, the recombinant wild-type APE1 (WT APE1) was able to generate 
two cleavage products of Oligo LA-4RNA (Figure 12B, lane 5-8) more efficiently than in 
Oligo LA and Oligo IA-RNA. Also, the identity of the two lOnt products were shown to have 
resulted from the RNA endoribonuclease and 3'phosphodiesterase activities of WT APE1 
cutting in between rUpA dinucleotides with 3 'phosphate and the subsequent removal of die 
phosphate group to yield the product with 3 hydroxyl group (Figure 12B).
By measuring ratio of the intensity of the products (lOnt 3 '-P and lOnt 3 '-OH) over 
those of the substrate plus product, we could quantify the degree of reduction observed in
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these variants as compared to that of WT APE1 at optimal reaction time of 30 mins. It was 
found that the 3'RNA phosphodiesterase activities of the structural variants D70A, Y171F, 
D308A, H309S, D210N, H309N, N68A, D283N, and F266A were reduced (Figure 14 and 
Table 5) from an average of three experiments (n=3); confirming that these residues are 
indeed critical for 3'RNA phosphodiesterase activity of APE1. The list of APE1 structural 
variants (Table 5), except D308A and N68A (n=2), also showed decrease in 
endoribonuclease activity thus confirming the importance of these residues and the roles they 
play in the RNA incision activity of APE1.
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Figure 15. Endoribonuclease and 3'phosphodiesterase activities of structural variants of APE1 on 
Oligo IA-4 RNA substrate. 0.1 pg of WT APE1 and structural variants of APE1 were tested against 
5' ^ y-32P-radiolabeled ssRNA (100,000 CPM) in total reaction volume of 15 pi between 0 -3 0  mins.
The degree of reduction in endoribonuclease and 3'phosphodiesterase activities 
shown for each structural variant (Table 5) gave account for the corresponding importance of 
that specific residue. For example, most of the structural variants showed reduction in 
3'RNA phosphodiesterase activity relative to the WT APE1. The quantification of the 
appearance of product at 30 mins optimal time over a total intensity of substrate and product 
showed that these variants possessed the following 3'phosphodiesterase activity relative to 
the WT APE1 (100%): H309N, D283N, N68A, D210N, and Y171F showed greater
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reduction in activity (7%, 3%, 5%, 14% and 11%, respectively) than the variants H309S, 
D308A, F266A and D70A (19%, 28%, 37%, and 31%, respectively). Relative to 
endoribonuclease activity of WT APE1 these variants exhibited ~ 2-fold reduction in activity; 
conversely N68A and D308A showed increase (153%, and 168%, respectively) in activity. 
These results suggest that the active sites for the endoribonuclease and 3 'phosphodiesterase 
functions of APE1 are likely to overlap, with both activities being reliant on H309, D283, 
D210, F266 and Y171. However, observations for N68 and D308 showed enhanced APE1 
endoribonuclease activity but substantial reduction in 3 'phosphodiesterase activity, 
suggesting that the catalytic mechanism for the two ribonuclease activities is distinguishable. 
Nonetheless, this experiment with the 5'-labeled substrate warrants future investigations on 
3 'phosphodiesterase activity of APE1.
Table 5: A summary of endoribonuclease and 3 'phosphodiesterase activities of APE1 
structural variants on 17nt Oligo 1A-4 RNA. *The ratios of intensity of the products (3 'P 
and 3'OH) at 10 nt over those of the substrate plus product were determined using OptiQuant 
software (Hewlett Packard, Palo Alto, CA).
APE1 Variant Relative 3 ' Phosphodiesterase 
Activity (%) at rUA site
Relative Endoribonuclease 
Activity (%) at rUA site
WT 100 100
H309S 19.4 ±0.10 69.4 ±0.88
H309N 7.0 ± 0.02 51.8 ±0.58
D283N 3.0 ± 0.02 38.2 ±0.17
N68A 5.0 ± 0.03 152.5 ± 1.13
D308A 28.2 ±0.16 167.5 ± 0.64
D210N 14.1 ±0.02 69.4 ± 0.23
F266A 37.4 ±0.65 83.3 ±0.11
D70A 31.1 ±0.18 51.5 ±0.06
Y171F 11.3 ±0.03 51.1 ±0.08
Data obtained from Figure 15 and replicates (n=3 ± Standard Error); N68A and D308 (n=2 ± 
Standard deviation)
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3.3.2 3'RNA phosphodiesterase activity of the population variants of APE1
A few APE1 variants identified from the human population were considered to be 
associated with increased disease susceptibility (Hadi et al. 2000). In this study a total of ten 
variants were tested (D148E, G306A, G241R, L104R, E126D, Q51H, 164V, P31 IS, R237C, 
and PI 12L). From an average of usually three experiments (n=3) D148E, G306A, G241R, 
L104R, E126D, Q51H, 164V, and P31 IS (Figure 16, Table 6) showed significant reduction 
in both endoribonuclease and 3 RNA phosphodiesterase activities. However, only two 
experiments (n=2) were done for R237C and PI 12L variants which seemed to show 
enhanced endoribonuclease and 3 'RNA phosphodiesterase activities (data not shown). Such 
observations would need to be confirmed in future studies.
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Figure 16. Endoribonuclease and 3'phosphodiesterase activities of APE1 population variants on 
Oligo IA-4 RNA substrate. 0.1 pg of WT APE1 and APE1 population variants were tested against 5' 
y-32P-radiolabeled ssRNA (100,000 CPM) in total reaction volume of 15 pi between 0 -  30mins.
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The quantification of the decay product at 30 minutes time point over the total 
intensity of substrate and product showed that these variants possessed the following 
3'phosphodiesterase activity relative to the WT APE1 (100%): D148E, G241R, L104R, 
E126D and Q51H showed substantial reduction (4%, 5%, 4%, 5%, and 3%, respectively) in 
activity; whereas G306A, I64V and P31 IS showed moderate reduction (11%, 18%, and 15%, 
respectively). Relative to the WT APE1, the following variants exhibited substantial 
reduction in their endoribonuclease activity against Oligo IA-4 RNA: D148E, G306A, 
G241R, and E126D were noticeably reduced to ~ 2% in activity, whereas Q51H, 164V, and 
P311S also had modestly reduced activity (32%, 28%, and 44%, respectively). LI 04R 
showed near abrogation (~ 1%) of its endoribonucleolytic activity. Interestingly, both L104R 
and E126D variants (Figure 16B) possess altered cleavage sites on the RNA substrate as both 
variants lost common cleavage sites and gained additional unique cleavage sites, 
respectively, as compared to the cleavage sites of wild-type APE1; these results appear to be 
very similar to past results against 182 c-myc CRD RNA and Oligo IB RNA substrates (Kim 
et al. 2009). In addition to these altered cleavage patterns, these two variants maintained 
RNase activity even in the presence of a powerful RNase inhibitor, RNasin (Kim et al. 2009). 
RNasin is a small peptide inhibitor of RNase activity which functions by the non-covalent 
bonding of RNasin to RNases (Kim et al. 1999). Wild-type APE1 no longer possesses RNase 
activity in the presence of RNasin. The ability of L104R and E126D to cleave in the presence 
of RNasin suggests that these variants may be more active in their RNase activity than APE 1.
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Table 6: A summary of endoribonuclease and 3 'phosphodiesterase activities of APE1 
population variants on 17nt Oligo IA-4 RNA. *The ratios of intensity of the products (3'P 
and 3 'OH) at 10 nt over those of the substrate plus product were measured using OptiQuant 
software (Hewlett Packard, Palo Alto, CA) to quantify activities.
Variant Relative 3 ' Phosphodiesterase 
Activity (%) at rUA site
Relative Endoribonuclease 
Activity (%) at rUA site
WT 100 100
D148E 4.0 ± 0.01 2.0 ± 0.36
G306A 11.4 ±0.06 2.0 ± 0.02
G241R 5.0 ± 0.24 2.0 ±0.36
L104R 4.0 ± 0.36 1.0 ±0.30
E126D 5.0 ± 0.06 2.0 ±0.10
Q51H 3.0 ±0.17 32.1 ±0.17
I64V 18.1 ±0.06 28.2 ± 0.07
P311S 15.2 ±0.16 44.3 ±0.17
Data obtained from Figure 16 and replicates (n=3 ± Standard Error)
3.4 Discussion
As described by Kim et al. (2011), the degree of reduction observed in RNA incision 
activity for each structural mutant on various RNA substrates (i.e. determined the reduction 
in endoribonuclease activity of WT APE1 against c-myc CRD RNA) gave account for the 
corresponding importance of that specific residue. Thus, single amino acid substitutions can 
drastically change substrate specificity and alter the activity of enzyme. Studies have 
demonstrated that DNA repair genes are frequently subjected to single nucleotide 
polymorphisms and single amino acid substitutions such as in the case of RNase L which has 
been shown to play a role in the development of prostate cancer (Silverman 2003). APE1 is 
no different: 19 population variants of APE1 have been identified (Hadi et al. 2000, Wilson 
et al. 2011), and several of these variants have demonstrated altered endoribonuclease 
activity in vitro (Kim et al. 2011). Defects in APE1 activities or altered expressions of APE1
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on DNA repair genes are associated with cancer proliferation and can influence the 
sensitivity of the tumor cells to therapeutic reagents (Bapat et al. 2009). In this regard, there 
are several examples of how mutations can alter the activity and reaction specificity of DNA 
repair enzymes, while RNA repair is still not as well understood.
This study was undertaken to investigate the roles played by several key DNA 
nuclease active-site amino acids on the 3 'RNA phosphodiesterase and endoribonuclease 
activities of APE1, with the goal of understanding the catalytic mechanism for RNA cleavage 
by APE1. A total of nineteen purified APE1 variant proteins containing single amino acid 
substitutions (Erzberger et al. 1999) were assessed in this study to determine whether there is 
a correlation between APE1 endoribonuclease and 3'RNA phosphodiesterase activities.
Using Oligo LA-4 RNA as substrate, our results demonstrated that mutation at H309, D283, 
D210, D70, and Y171 appeared to substantially reduce APE1 ’s endoribonuclease activity. 
Mutation at F266 had a small effect, and substituting N68 and D308 to alanine seemed to 
increase its endoribonuclease activity. Using Oligo IA-4 RNA as substrate, mutation at 
residues known to be critical for nuclease activities of APE1 (H309, D283, D201, D70,
Y171, N68, D308) seemed to significantly reduce 3'RNA phosphodiesterase activity of 
APE1. Also, using Oligo IA-4 RNA as substrate, all the known population variants of APE1 
exhibited significant reduction in both endoribonuclease and 3 'RNA phosphodiesterase 
activities.
The reduction in endoribonuclease activities observed with the tested APE1 structural 
variants (Table 7) and human population variants (Table 8) on Oligo IA-4 RNA correlated 
well with previous studies that assessed the same panel of APE1 structural variants for their 
ability to cleave 5 '-32P-labeled c-myc 1705-1792 CRD RNA substrate (Kim et al. 2009 and 
2011).
Table 7 shows that mutation at H309, D283, D210, F266, D70, and Y171 appeared to 
greatly reduce APE1 ’s endoribonuclease activity on both c-myc 1705-1792 CRD RNA and 
Oligo IA-4 RNA, confirming that these residues are indeed critical for endoribonuclease 
activity of APE 1.
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Table 7: Summary of the endoribonuclease activity of APE1 structural variants as 
compared to that of 100% WT-APE1 activity. Values indicated as percent reduction.
APE1 structural Fold reduction in Fold reduction in
mutants endoribonuclease activity endoribonuclease activity
against c-myc 1705-1792 against Oligo IA-4 RNAb 
CRD RNA*
H309S 16.7 69.4
H309N UD 51.8
D283N 25.0 38.2
N68A AB 152.5
D308A 11.1 167.5
D210N 0.01 69.4
F266A AB 83.3
D70A 1.80 51.5
Y171F 5.65 51.2
AB, abolished; and UD, undetermined as compared to that of WT APE1.
8 Information obtained from the literature; fold converted to percentage (Kim et 
al. 2009)
b Data obtained from Fig. 15 a, b, c, d, and replicates.
In contrast to the increase in incision activity shown on Oligo IA-4 RNA, mutation at N68 
and D308 showed greater reduction in endoribonuclease activity against c-myc CRD RNA. 
Apparently, N68 is thought to create a favorable environment for catalysis through its 
hydrogen bonding ability to D210 and H309, with D210 participating in the generation of a 
nucleophile (Erzberger and Wilson 1999, Nguyen et al. 2000). Thus, a mutation to alanine 
would be considered harmful for RNA incision activity (Kim et al. 2012). D70 and D308 are 
predicted to coordinate metal ions during DNA incision and are thought to orient the 
substrate, to stabilize the transition state, and to facilitate the dissociation of the product 
(Erzberger et al. 1999, Kim et al. 2011). D283 has been described to play a role in the 
orientation of H309 through hydrogen bonding and act to stabilize its positive charge which
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indicates that the significance of D283-H309 dyad in RNA cleavage is critical (Hadi et al. 
2000). F266 may serve a similar role in recognizing RNA bases as it does during abasic 
DNA incision through its hydrophobic pocket comprised of F266, W280 and L282 (Hadi et 
al. 2002, Kim et al. 2012). In addition, F266 variant was shown to possess an enhanced 
DNA 3 'exoribonuclease activity compared to WT APE1 on a single stranded DNA-RNA 
hybrid (Oligo 1A-4 RNA) that can form a dynamic hairpin structure. Reduction in both RNA 
cleavage activities observed in Y171F variant confirms that the hydroxyl group on the phenyl 
ring is important in formation of hydrogen bonds to E96 that is critical in establishing the 
appropriate active site environment via hydrogen-bonding network involving Y171 
(Erzberger and Wilson 1999).
Table 8 shows that all the known population variants of APE1 exhibited significant 
reduction in endoribonuclease activity on both c-myc 1705-1792 CRD RNA and Oligo LA-4 
RNA substrates. Given that some of these variants have been associated with human 
diseases such as cancer and amyotrophic lateral sclerosis (ALS), further investigation into the 
possible link between ribonuclease activity of APE1 and alteration in cell phenotype should 
be warranted (Hadi et al.2002).
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Table 8: Summary of the endoribonuclease activity of APE 1 human population variants as 
compared to that of 100% WT-APE1 activity. Values indicated as percent reduction.
APE1 human % reduction in % reduction in
population variants endoribonuclease activity endoribonuclease activity
against c-myc 1705-1792 against Oligo IA-4 RNA 
CRD RNA*
D148E 6.8 2.0
G306A 5.5 2.0
G241R 12.2 2.0
L104R AB 1.0
E126D 8.0 2.0
Q51H 12.5 32.1
I64V ND 28.2
P311S UD 44.3
AB, abolished; and UD, undetermined; ND, non-detectable level of activity as
compared to that of WT APE1.
* Information obtained from the literature (Kim et al. 2009) 
b Data obtained from Fig. 16a, b, c, and replicates.
Of the listed variants, the activities of Q51H and I64V were also notably reduced against c- 
myc RNA and Oligo IA-4 RNA, though these variants are known to be located in the redox 
domain of the 61 N-terminal amino acids (Izumi et al. 2005), which imply that they are 
unlikely to have effects on nuclease function, including ribonuclease activity. The reason 
behind such reduction for a specific dinucleotide sequence is unknown and warrants further 
investigation on identifying regions of APE1 that give cleavage specificity. However, both 
results showed that Q51H and I64V have reduced RNA incision activity and warrants further 
characterization of their properties. Altered cleavage sites were observed on c-myc and Oligo 
IA-4 RNA substrates for the variants L104R and E126D. Such observations suggest that 
these residues are important in giving endoribonuclease activity, as well as in giving the 
specificity of cleavage of APE1. For instance, Shinmura et al. (2001) have identified two
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mutants I64V and D148E in primary lung cancer. Pieretti et al. (2001) detected two mutants 
Q51H and D148E in both ovarian and endometrial cancers. How this occurs, 
mechanistically, and the exact function APE1 is playing in cancer requires further 
investigation.
In addition to the DNA endonuclease activity, APE1 possesses DNA 3'- 
phosphodiesterase activity (3 '-end cleansing activity) (Suh et al. 1997; Ramana et al. 1998; 
Izumi et al. 2000). It has been shown that the removal of the oxidatively damaged base is not 
the rate-limiting step, but rather it is APEl’s phosphodiesterase activity that is the rate- 
limiting step in BER repair of oxidative DNA damage (Suh et al. 1997; Izumi et al. 2000, 
Fortini et al. 1999). Suh et al. (1997) compared two types of human APE1 activities in 
kinetics studies and found that the AP endonuclease activity was ~ 100-fold more efficient 
than 3 'DNA phosphodiesterase activity, which is comparable with the kinetic analysis of 
APE1 towards Oligo LA RNA in Chapter 2 (Figure 11). The implication of an APE1 variant 
affected only in the 3 'RNA phosphodiesterase activity would make it possible to test the 
significance of phosphodiesterase activity of APE1 in the control of mRNA stability in cells. 
For instance, in this study, we report a ~3-fold reduction in 3'phosphodiesterase activity of 
D70A variant as compared to the WT APE1 on single-stranded Oligo IA-4 RNA, which 
contrasts the report by Castillo-Acosta et al. (2009) who revealed that D70A variant was ~7- 
fold more efficient as a 3 'phosphodiesterase than WT APE1 on a nicked DNA duplex 
substrate. This suggests that mutations at residues (H309, D283, D201, Y171, N68, and 
D308), for instance substituting D70 to alanine that showed reduction in 3'phosphodiesterase 
activity most likely play a key role in the catalytic reaction steps of RNA cleavage of APE1. 
We are aware that the available data are not sufficient to understand the role of critical 
residues during 3 'end cleavage and further structural and biochemical experimentation will 
be required to fully understand the 3 'phosphodiesterase activity of APE1.
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CHAPTER 4
Further characterization of ribonuclease activities of APE1
4.1 Introduction
4.1.1 Known inhibitors of APE1 functions on 3'RNA phosphodiesterase activity
As a first step towards understanding the role of 3 'RNA phosphodiesterase activity of 
APE1 in cells, we proceeded to find compounds which can inhibit 3'RNA phosphodiesterase 
activity. We began by searching for compounds that are known to inhibit other functions of 
APE1, including inhibition of nuclease activity of APE1. Myricetin, methoxyamine 
hydrochloride and E3330 small molecule inhibitors are known to be specific for APE1, in 
that they do not appear to interact with DNA and have no activity against Escherichia coli 
endonuclease IV (a functional homolog with no sequence or structural homology to APE1). 
Myricetin and methoxyamine HC1 have been found to be potent inhibitors of AP site 
cleavage activity in HeLa whole cell extract assays, leading to accumulation of AP sites in 
vivo in cancer cells (confirming target inhibition) and increase the effect of cytotoxicity of 
alkylating agents in cancer cell lines (Mohammed et al. 2011, Simeonov et al. 2009). The 
following is a brief summary of the small molecule inhibitors used in this study.
APE1 DNA repair domain inhibitors
Mvricetin
Myricetin (3,3 ',4',5,5 ',7-Hexahydroxyflavone) is one of the six major flavonoids 
found in many foods and beverages that are nutritionally interesting primarily for their 
antioxidant activities (Ross et al. 2002). Myricetin is a cell-permeable flavanoid that displays 
anti-inflammatory, anti-diabetic and anti-cancer properties (Cushnie et al. 2005). A study 
has identified myricetin as a potent inhibitor of DNA APE1 incision capacity (>80%) relative 
to their experimental control (no inhibitor, DMSO control) reaction (Simeonov et al. 2009).
It was identified as selective, direct inhibitor of APE1 incision activity shown to inhibit AP 
site cleavage activity of whole cell protein extracts isolated from HEK 293T and HeLa cell 
lines, and to enhance the cytotoxic and genotoxic potency of the alkylating agent 
methylmethane sulfonate (MMS). Thus, its specificity for APE 1 exemplifies myricetin’s
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prospect as a biological probe for APE1 function (Simeonov et al. 2009). It is also known to 
inhibit a variety of DNA polymerases, RNA polymerases, reverse transcriptases, telomerases, 
kinases, helicases, and phosphodiesterase 1-4 in guinea pigs (IC50 < 40 pM) (Shinozuka et 
al. 1988, Ono et al. 1990, Chu et al. 1992, Menichincheri et al. 2004; Griep et al. 2007; Ko 
WC et al. 2004),
Methoxyamine Hydrochloride (MX)
Methoxyamine HC1, is described as a nonspecific indirect inhibitor of APE1, binds 
permanently to AP sites in DNA and prevents APE1 (and endonuclease IV) from processing 
the adducted AP lesion (Liu and Gerson 2004). Methoxyamine HC1 is known to potentiate 
the effect of an anti-cancer agent, temozolomide, in vitro (Tavema et al. 2001; Fishel et al. 
2007) and in tumour xenografts (Liu and Gerson 2004; Yan et al. 2007). It has undergone 
phase I clinical trials in combination with a chemotherapy drug called pemetrexed (Anthony 
et al. 2009) and temozolomide (Sawides et al. 2010) in patients with advanced refractory 
cancer.
APE1 redox domain inhibitors
E3330
Previous studies have established E3330 as a small molecule inhibitor of the 
APE 1 /Ref-1 DNA redox function. It specifically and selectively blocks APE 1-mediated 
reduction of various transcription factors to their activated state (Zou and Maitra 2008; Luo 
et al. 2008; Zou et al. 2009; Nyland et al. 2010). E3330 exposure has been demonstrated to 
reduce tumour cell growth (Saitou et al. 2005), migration (Zou and Maitra 2008) and 
angiogenesis (Zou et al. 2009). A number of its analogues with improved potency are 
currently under evaluation (Kelley, Georgiadis, and Fishel 2011).
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4.1.2 Identifying the critical amino acid residues responsible for the abasic RNA 
activity of APE1
APE1 is able to endoribonucleolytically cleave single-stranded abasic (AP) RNA and 
may participate in an RNA quality control process (Berquist et al. 2008; Vascotto et al. 2009; 
Kim et al. 2011). In an effort to further understand the ribonuclease activity of APE1 and to 
determine the critical amino acid residues responsible for the abasic activity of APE1, we 
challenged the WT APE1 and a number of APE1 variants on 5 '-labeled 34-mer abasic RNA.
4.2 Methods
The methods used in this Chapter are essentially those described in Chapters 2 and 3 
with the following modifications.
4.2.1 Studies using inhibitors - E3330, Myricetin and Methoxyamine Hydrochloride
For inhibitor studies, APE1 (0.1 pg/pL) was pre-incubated with inhibitor (0—100 
pg/pL) for 10 min on ice-cold before addition of 2 pi of labelled Oligo LA-4 RNA (Figure 
6c) substrate (100,000 CPM). Reactions were incubated for 30 min at 37°C and followed by 
addition of 40 pi of RNA stop dye. Products were analyzed on 15% denaturing 
polyacrylamide gel. The gel was run at 20 mAmp for 85 minutes in 0.5x TBE buffer. The 
gel was put in a -80°C freezer on one glass plate and exposed to a Phosphor Screen 
overnight. Images of gels were taken using the Cyclone Phosphor Imager (PerkinElmer, 
Waltham, MA) with OptiQuant software (Hewlett Packard, Palo Alto, CA). Post editing of 
the images was done using CorelDRAW software (Corel, Ottawa, ON).
4.2.2 AP site incision for ssRNA
Recombinant WT APE1 and structural variants (N68A, H309N, F266A, H309S, 
D283N, D210N, D308A, Y171F, D70A); also WT APE1 and human population variants 
(D148E, L104R, E126D) were incubated with PAGE-purified 5'-32P-labeled abasic single­
stranded 34F RNA (5 '-CUGCAGCUGAUGCGCFGUACGGAUCCCCGGGUAC-3') at 
37°C in 25 mM MOPS (pH 7.2), 100 mM KC1, 1 mM MgCl2 for the either specified times 
(0, 5,10, and 30 min) or specified concentrations (0.1, 0.25,0.5 pg/pL). These reactions 
were stopped at 37°C for 5 min. Reaction with 34F RNA contained 0.1 pg/pL APE1.
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Reaction were inhibited by the addition of RNA stop dye and then heated at 95 °C for 5 min. 
Reaction products were resolved using 15% polyacrylamide urea denaturing gel. The gel 
was put in an 80°C freezer on one glass plate and exposed to a Phosphor Screen (Packard, 
Meriden, CT). Exposure was typically done over night in the freezer. On the following day, 
an image of the gel was taken using the Cyclone Phosphor Imager (PerkinElmer, Waltham, 
MA) with OptiQuant software (Hewlett Packard, Palo Alto, CA). Post editing of the images 
was done using CorelDRAW software (Corel, Ottawa, ON).
4.3 Results
4.3.1 Assessing known inhibitors of APE1 functions on 3 'RNA phosphodiesterase 
activity
In this study, 5 '-radiolabeled Oligo IA-4 RNA substrate was used to examine the 
possible inhibitory effect of the small molecule inhibitors on 3'RNA phosphodiesterase 
activity of APE1 (Simeonov et al. 2009, Sultana et al. 2012, Zou et al. 2008). As previously 
mentioned in chapter 2, WT APE1 was able to generate two cleavage products of higher 
intensity in Oligo IA-4RNA (Figure 1 IB) than in Oligo LA and Oligo IA-RNA. Also, the 
identity of the two 10 nt products were shown to have resulted from the RNA 
endoribonuclease and 3'phosphodiesterase activities of WT APE1 cutting in between rUpA 
dinucleotides generating a 3 'phosphate and a 3 hydroxyl group product, respectively (Figure 
12B). In contrast, the RNase A marker which is known to possess only the endoribonuclease 
activity had no 3'RNA phosphodiesterase activity (Barnard 1969; Sorrentino and Libonati 
1994).
Each of the small molecules were tested at various concentrations (0 .1-100 pM) on 
0.1 pg/pL of APE1 and 0.25 pM of RNase A (Figure 17). Inhibitors with specificity for 
APE1 (lanes 6-10) were expected to show reduced activity relative to the control (lane 5). 
Methoxyamine HC1 and E3330 had no effect up to 100 pM. In contrast, at 10 and 100 pM, 
myricetin completely abrogated the 3'RNA phosphodiesterase activity of APE1 while little 
effect was seen on endoribonuclease activity of APE1. At 10 and 100 pM, myricetin also 
significantly inhibited the endoribonuclease activity of RNase A.
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The dose-experiment for each of the small molecule inhibitor was conducted only 
once. Therefore, no reliable conclusion (kinetic analysis) can be drawn from this single 
experiment. Nonetheless, the experiment with myricetin warrants future investigation.
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Figure 17. Effect of small molecules on the endoribonuclease and 3 'RNA phosphodiesterase 
activities of APE1. (A) Structure of OligolA-4 RNA substrate. Arrows indicate the expected 
cleavage sites by APE1 and RNase A. Lanes 5 to 10 had 0.1 pg APE1 and lanes 11 to 15 had 0.25 
pM RNase A. In addition, various concentrations of myricetin, (B) methoxyamine HC1 (MX) (C), 
and E3330 (D) as indicated, were added to samples in lanes 6-10 and lanes 12-15.
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4.3.2 Determining the critical amino acid residues responsible for the abasic RNA 
activity of APE1
The structural variants of APE1 (D148E, L104R, E126D, N68A, H309N, F266A, 
H309S, D283N, D210N, D70A, D308A, and Y171F) that were previously mentioned in 
section 3.2 were also challenged with the 34F abasic single stranded RNA substrate (Figure 
18A), where F denotes the position of abasic site analog tetrahydrofuran (Figure 18B). Each 
experiment (Figure 19 - 24) was conducted only once. Therefore, no reliable quantitative data 
can be drawn from these single experiments. Nonetheless, the qualitative observations 
presented here for the 5'-radiolabeled 34mer abasic RNA substrate warrant future 
investigations on the endoribonuclease activity of APE1 on abasic RNA.
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Figure 18. Predicted secondary structures of 34mer abasic ssRNA substrate. (A) Two predicted 
secondary structures of 34F ssRNA as determined using Mfold are shown. dG represents the 
minimum free energy for folding. (B) F denotes position of synthetic abasic site analog 
tetrahydrofuran, which mimics a stalled RNA transcription (encircled with a dotted triangle in (A)).
When subjected to a standard electrophoretic assay, APE1 showed abasic RNA 
activity toward 34-mer abasic RNA substrate as previously indicated in a study done by 
Berquist et al. (2008). Our work further revealed that APE1 possesses endoribonuclease 
activity against the 34-mer abasic RNA because we used a high resolution gel. Berquist et 
al. (2008) had used a small gel and hence only focused on observing abasic RNA activity.
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The authors had missed observing the endoribonuclease activity of APE1 on 34-mer abasic 
RNA, i.e., cleavage products at 4CA, 8UG, and 18UA.
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Figure 19. Dose-dependent effect of WT APE1 and D148E APE1 variant on 34F AP-RNA substrate. 
(A) 0.1 pg of APE1 WT (lanes 5 -  7), 0.25 pM RNase A (lane 11), and 1 U RNase T1 (lane 12) were 
tested against 25 nM of 5 '-y-32P-labeled 34F AP-RNA in a total reaction volume of 20 pi for 30 mins 
at 37 °C. The products were resolved on a 15% polyacrylamide gel as described in section 2. (B) 
Secondary structure of 34F AP-RNA and the positions of cleavage sites for WT APE1 relative to 
markers RNase A and RNase T1. Symbols represent strong and weak cleavage.
Figure 19 showed that the abasic RNA activity was decreased when higher 
concentration (0.5 and 1.0 pg) of APE1 was used. The endoribonuclease activity at 4CA 
remained the same while 18UA and 8UG decreased slightly. One noteworthy observation 
was that there is a cleavage product of weaker intensity at 3 nt G that increases in intensity 
relative with increasing concentration (0.5 and 1.0 pg) of APE1. The 3 nt G cleavage 
product may have resulted from RNA 3 'exonuclease activity. But further experiments would 
need to be conducted to confirm this. The common APE1 variant D148E that occurs in about 
50% of the human population has completely abolished endoribonuclease activity on 34F
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AP-RNA relative to the WT APE1. This is consistent with previous results (Kim et al. 
2009). Figure 20, of time-dependent experiments further confirmed the results for D148E 
variant.
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Figure 20. Time-dependent effect of WT APE1 and D148E APE1 variant on 34F AP-RNA 
substrate. (A) 0.1 pg of APE1 WT (lanes 5 - 8), 0.1 pg of D148E variant (lanes 9 - 12) and 0.25 pM 
of RNase A (lane 14) were tested against 25 nM of 5'-y-32P-labeled 34F AP-RNA in a total reaction 
volume of 15 pi for 30 mins at 37 °C. The products were resolved on a 15% polyacrylamide gel as 
described in section 2. (B) Secondary structure of 34F AP-RNA and the positions of cleavage sites 
for D148E (lane 9) relative to WT APE1 (lane 8). Symbols represent strong and weak cleavage.
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Figure 21. Dose-dependent effect of WT APE1, L104R and E126D APE1 variants on 34F AP-RNA 
substrate. (A) 0.1 pgof APE1 WT (lanes 4), 0.1 pg of L104R (lanes 5 - 7), 0.1 pg of E126D (lane 8 
-  10) variants and 0.25 pM of RNase A (lane 11) were tested against 25 nM of 5'-y-32P-labeled 34F 
AP-RNA in a total reaction volume of 15 pi for 30 mins at 37 °C. The products were resolved on a 
15% polyacrylamide gel as described in section 2. (B) Secondary structure of 34F AP-RNA and the 
positions of cleavage sites for L104R (lane 5) and E126D (lane 8) variants relative to WT APE1 (lane 
5). Symbols represent strong and weak cleavage.
Figure 21 shows that both L104R and E126D retained their abasic RNA activity but 
have substantially reduced endoribonuclease activity at 4CA, 18UA, and 8UG relative to the 
WT APE1. For E126D, the cleavage pattern showed a laddering effect which is suggestive 
of 3 'exoribonucleolytic decay.
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Figure 22. Dose-dependent effect of WT APE1, N68A and H309N APE1 variants on 34F AP-RNA 
substrate. (A) 0.1 pg of APE1 WT (lanes 4), 0.1 pg of N68A (lanes 5 - 7), 0.1 pg of H309N (lane 8 -  
10) variants and 0.25 pM of RNase A (lane 11) were tested against 25 nM of 5'-Y*32P-labeled 34F 
AP-RNA in a total reaction volume of 15 pi for 30 mins at 37 °C. The products were resolved on a 
15% polyacrylamide gel as described in section 2. (B) Secondary structure of 34F AP-RNA and the 
positions of cleavage sites for N68A (lane 5) and H309N (lane 8) variants relative to WT-APE1 (lane 
4). Symbols represent strong and weak cleavage.
Figure 22 shows that N68A retained its abasic RNA but has reduced 
endoribonuclease activity. However, H309N had moderately reduced abasic RNA activity 
and endoribonuclease activity relative to the WT APE1. H309N also showed altered 
cleavage products at 19AC and 13CG.
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Figure 23. Dose-dependent effect of WT APE1, F266A and H309S APE1 variants on 34F AP-RNA 
substrate. (A) 0.1 pg of APE1 WT (lanes 4), 0.1 pg of F266A (lanes 5 - 7), 0.1 pg of H309S (lane 8 — 
10) variants and 0.25 pM of RNase A (lane 11) were tested against 25 nM of 5'-y-32P-labeled 34F 
AP-RNA in a total reaction volume of 15 pi for 30 mins at 37 °C. The products were resolved on a 
15% polyacrylamide gel as described in section 2. (B) Secondary structure of 34F AP-RNA and the 
positions of cleavage sites for F266A (lane 5) and H309S (lane 8) variants relative to WT-APE1 (lane
4). Symbols represent strong and weak cleavage.
Figure 23 shows that F266 retained its abasic RNA activity but has substantially 
reduced endoribonuclease activity. H309S had substantially reduced abasic RNA activity 
and moderately reduced endoribonuclease activity, which is similar to the reductions shown 
for H309N relative to WT APE1. This suggests that H309 is an important residue for this 
activity.
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Figure 24. Time-dependent effect of WT APE1, D283N and D210N APE1 variants on 34F AP-RNA 
substrate. (A) 0.1 pgof APE1 WT (lanes 4 - 5), 0.1 pgof D283N (lanes 6-9), 0.1 pgofD210N 
(lane 10 -  12) variants and 0.25 pM of RNase A (lane 13) were tested against 25 nM of 5'-y-32P- 
labeled 34F AP-RNA in a total reaction volume of 15 pi for 30 mins at 37 °C. The products were 
resolved on a 15% polyacrylamide gel as described in section 2. (B) Secondary structure of 34F AP- 
RNA and the positions of cleavage sites for D283N (lane 5) and D210N (lane 8) variants relative to 
WT-APEl (lane 5). Symbols represent strong and weak cleavage.
Figure 24 shows that both D283N and D210N variants had no abasic RNA activity 
and lost their endoribonuclease activity with increasing time (5 to 30 mins).
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Figure 25. Time-dependent effect of WT APE1, D308A and Y171F APE1 variants on 34F AP-RNA 
substrate. (A) 0.1 pg of APE1 WT (lanes 4 - 5), 0.1 pg of D308A (lanes 6 - 7), O.lpg of Y171F (lane 
8-9) variants and 0.25 pM of RNase A (lane 10) were tested against 25 nM of 5'-y- P-labeled 34F 
AP-RNA in a total reaction volume of 15 pi for 30 mins at 37 °C. The products were resolved on a 
15% polyacrylamide gel as described in section 2. (B) Secondary structure of 34F AP-RNA and the 
positions of cleavage sites for D308A (lane 5) and Y171F (lane 8) variants relative to WT-APEl (lane
5). Symbols represent strong and weak cleavage.
Figure 25 shows that D308A retained its abasic RNA activity but had moderately 
reduced endoribonuclease activity. However, Y171F showed no abasic RNA activity and 
also lost its endoribonuclease activity with increase time (5 to 30 mins).
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4.4 Discussion
4.4.1 Myricetin inhibits the 3'RNA phosphodiesterase activity of APE1
Small molecule inhibitors are potentially powerful tools in dissecting the various 
functions of APE1 in cells. In this study, E3330 showed no effect on either endoribonuclease 
or 3 'RNA phosphodiesterase activity in vitro, which is consistent with its specificity on 
inhibiting the redox function of APE1 and not on its nuclease activity. Our preliminary 
results showed that Myricetin but not Methoxyamine HC1 is capable of inhibiting the 
3 'phosphodiesterase activity of APE1. Table 9 summarizes the observations made from the 
electrophoretic assays (Figure 17) that were used to assess the known inhibitors of 
APE 1 function on APE1 RNA cleavage activities.
Table 9: Summary on the effect of small molecules
Inhibitor Structure Inhibition on
activity of APE 1
Inhibition on 
3'RNA
Phosphodiesterase 
activity of APE 1
Inhibition on 
endoribonuclease 
activity of RNase• M P i i i
3,5,7 -  Trihydroxy- 
2-(3,4,5-
trihydroxyphenyl)
-  4-chromenone 
(Myricetin)
cfy=o
oX
r  o h  Y e s
-XX.
''O H
Yes Yes
Methoxyamine
Hydrochloride
(2E)-2-[(4,5-
Dimethoxy-2-
methyl-3,6-dioxo-
1,4-cyclohexadien-
yl)methylene]-
undecanoic acid
(E3330)
0
0
1 N o No No
Inhibition of APE1 RNA cleavage is indicated as Yes/No
63
CHAPTER 4 -  FURTHER CHARACTERIZATION OF RIBONUCLEASE ACTIVITIES
OFAPE1
Here we demonstrated that Myricetin, one of the major flavonols in red wine can 
potentially be used to understand the significance of 3 'RNA phosphodiesterase activity of 
APE1 in cells. Myricetin is a potent inhibitor of AP-DNA site cleavage activity of APE1 that 
is reported to inhibit 50% of APE1 incision activity in vitro, as well as >80% in HEK293T 
and HeLa whole cell extracts, and exhibit potentiating effects of MMS toxicity (Simeonov et 
al. 2009). Molecular modeling studies indicated that Myricetin docks onto the active site of 
APE1 but the rigid structural feature of the molecule lacks anchoring groups and therefore 
resulted in numerous possibilities for docking orientations without shape complementarity 
conflicts (Sultana et al. 2012; Simeonov et al. 2009). Myricetin is known to have numerous 
other targets besides APE1 in cells; therefore, it has not been considered a very promising 
agent with selectivity or specificity as an APE1 inhibitor (Simeonov et al. 2009). Our results 
showed that both the endoribonuclease activity of RNase A and 3'RNA phosphodiesterase 
activity of APE1 were inhibited by Myricetin, suggesting that these two nuclease activities 
utilize a similar catalytic mechanism. Understanding how Myricetin acts as an inhibitor in 
such cases will help in understanding this catalytic mechanism.
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4.4.2 Critical amino acid residues responsible for the abasic RNA activity of APE1
Table 10 is a qualitative summary of the observed reduction in the endoribonuclease 
and AP-ssRNA incision activities of APE1 human population variants as compared to the 
WT A PEI.
Table 10: A summary of endoribonuclease and AP RNA incision activities of human 
population variants of APE1.
Variants of 
APE1
Removal of 
abasic site 
(F) against 34F 
AP-RNA(>)
Endoribonuclease 
Activity against 
34F AP-RNA(a)
Endoribonuclease 
Activity against 182 
nt c-myc RNA(b)
WT-APE1 Yes Yes Yes
D148E SmR AB SR
L104R SmR SR AB
E126D SmR SR SR
<a) Qualitative data obtained from Figure 20-21
<b) Information obtained from the literature (Kim et al. 2009)
SmR = small reduction; MR= moderately reduced; SR = substantially reduced; 
AB = abolished activity____________________________________________
The human population variant D148E has strong abasic RNA activity but has completely lost 
its endoribonuclease activity, which is comparable to past results (Kim et al. 2009, Table 10). 
Both L104R and E126D also had strong abasic RNA activity but significantly reduced 
endoribonuclease activity. The laddering effect shown on E126D-treated samples suggests 
that it may have 3 'exoribonuclease activity, which is also consistent with previous results 
(Kim et al. 2009). These variants are speculated to be associated with increased disease 
susceptibility (Hadi et al. 2000). Hence, the change in cleavage patterns warrants further 
investigations on their role in human diseases such as cancer and ALS (Hadi et al. 2002).
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Table 11, is a qualitative summary of the observed reduction in the endoribonuclease 
and AP-ssRNA incision activities of APE1 structural variants as compared to WT APE1.
Table 11: A summary of endoribonuclease and AP RNA incision activity of structural 
variants of APE 1.
Variants of 
APE1
Removal of 
abasic site 
(F) against 34F 
AP-RNA(,)
Endoribonuclease 
Activity against 
34F AP-RNA0 0
Endoribonuclease 
Activity against 182 
nt c-myc RNA(b)
WT-APE1 Yes Yes Yes
RNase A None Yes Yes
N6 8 A SmR MR AB
H309N SR MR AB (c)
F266A SmR SR AB
H309S SR MR AB
D283N AB AB AB
D210N AB AB AB
D308A SmR MR AB
Y171F AB AB AB
0 0  Qualitative data obtained from Figure 22 - 25
(b) Information obtained from the literature (Kim et al. 2011)
(c) Information obtained from the literature (Barnes et al. 2009)
SmR = small reduction; MR= moderately reduced; SR = substantially reduced; 
AB = abolished activity relative to 100% WT-APE1 activity.______________
The structural variant H309S and H309N had substantially reduced abasic RNA activity 
suggesting that H309 is an important residue for this activity. H309N and H309S also have 
reduced endoribonuclease activity and this is consistent with the previous reported 
endoribonuclease activity against c-myc CRD RNA (Barnes et al 2009; Table 11). N6 8 A 
appeared to retain its abasic RNA activity but has reduced endoribonuclease activity. The 
reduced endoribonuclease activity agrees with the previous finding by Kim et al. (2011). 
F266A appears to retain its abasic RNA activity but has substantially reduced
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endoribonuclease activity. D283N, D210N, and Y171F had no abasic RNA activity and also 
lost its endoribonuclease activity. D308A retained its abasic RNA activity but had 
moderately reduced endoribonuclease activity. The significant reduction observed for the 
endoribonuclease activity of APE 1 for F266A, D283N, D210N, Y171F, and D308A variants 
correlated well with a previous study by Kim et al. (2009) that tested these variants on c-myc 
CRD RNA substrate (Table 11). The fact that many mutations (D148, L104, E126, N6 8 , 
F266, and D308) clearly retained abasic RNA activity but significantly lost endoribonuclease 
activity suggested that these two nuclease activities are distinct and most likely act via 
different mechanism.
However, further investigation would be required to confirm these findings. For 
instance, a kinetic analysis developed from multiple experimental trials should better confirm 
the degree of reduction shown for the abasic and endoribonuclease activities by the APE1 
variants to give an account for the corresponding importance of that specific residue.
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CHAPTER 5
5.1 General overview
In addition to APE Is main function as an AP-DNA endonuclease, human APE1 can 
act as a 3'phosphodiesterase (Barzilay et al. 1995; Chen et al. 1991; Seki et al. 1992; Suh et 
al. 1997; Winters et al. 1992); however, the 3'phosphodiesterase activity is -200 fold times 
lower than its AP-DNA endonuclease activity (Evans et al. 2000). The 3 '-end activity 
initiates repair of single strand breaks (Izumi et al. 2000; Suh et al. 1997; Ramana et al.
1998), damage that may result from direct attack and fragmentation of deoxyribose residues 
in DNA by free radicals (Izumi et al. 2000; Wilson et al. 1995; Breen et al. 1995; Sancar et 
al. 2001). By hydrolyzing 3'-blocking fragments from oxidized DNA, APE1 produces 3'- 
hydroxyl nucleotide termini that are necessary for DNA repair synthesis and ligation at 
single- or double-strand breaks (Izumi et al. 2000; Kelley et al. 2001). In addition, APE1 is a 
weak 3 '-5' exonuclease (Harrison 1995), which might be physiologically significant against 
nucleoside analogues such as those used in anti-tumour therapy (Chou et al. 2000), and in the 
removal of mismatched nucleotides (Chou et al. 2002) incorporated by the main base 
excision repair polymerase, DNA polymerase p (polp), which has relatively low consistency 
and lacks proofreading exonuclease capability (OsherofF et al. 1999).
Recent studies have identified APE1 as possessing endoribonuclease activity against 
both mRNA and abasic RNA in vitro (Bames et al. 2009; Berquist et al. 2008; Kim et al.
2011). APE1 is also known to exist in multiple variants in the human population (Chapter 3). 
A few of these have been speculated to be associated with increased disease susceptibility 
(Hadi et al. 2000). For instance, the D148E variant can be found in different populations and 
different types of tumors (Shinmura et al. 2001; Pieretti et al. 2001; Hadi et al. 2000), along 
with L104R and E126D variants it has also been linked with ALS (Olkowski et al. 1998). 
Earlier investigation of the L104R and E126D APE1 variants showed that they generated 
altered cleavage patterns on c-myc CRD mRNA in vitro as compared to that of wild-type 
APE1; whereas, the D148E APE1 variant demonstrated complete abrogation of RNA 
cleaving activity against c-myc CRD mRNA (Kim et al. 2011). The purpose of this thesis 
was to study the possible 3' RNA phosphodiesterase and 3' exoribonuclease activities of 
APE1.
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5.2 APE1 possesses 3'RNA phosphodiesterase activity
The first objective of this research was to determine if APE1 possesses 3' RNA 
phosphodiesterase activity. Using three different RNA substrates (Oligo LA, Oligo IA-RNA, 
and Oligo LA-4 RNA), we clearly demonstrated for the first time the 3'RNA 
phosphodiesterase activity of APE1, namely the ability of APE1 to remove phosphate group 
at 3'end of RNA decay products to generate 3'hydroxyl, which was demonstrated by a 
kinetic data (Figure 11). Secondly, we have identified the critical amino acids responsible 
for 3 'phoshpodiesterase activity of APE1. Using Oligo IA-4R as substrate, mutation at 
residues known to be critical for nuclease activities of APE1 (H309, D283, D201, D70, and 
Y171) showed significantly reduced 3'RNA phosphodiesterase and endoribonuclease activity 
of APE1. This implies that these ribonuclease activities of APE1 share the same critical 
amino acid residues that are a part of the RNA catalytic mechanism. Thirdly, preliminary 
results revealed that myricetin is capable of inhibiting 3 'RNA phosphodiesterase activity at a 
dose of 10 pM and 100 pM. This small molecule inhibitor can potentially be used to 
understand the biological significance of 3' RNA phosphodiesterase activity of APE1 in 
vitro.
The newly discovered 3'RNA phosphodiesterase activity of APE1 has profound 
implication for further understanding the role of APE1 in mRNA metabolism and its 
mechanism of catalysis. Many nucleases that cleave RNA utilize metal ions for their catalysis 
(Wang et al. 2008). Therefore, one of the future experiments in characterizing the 
3'phosphodiesterase activity of APE1 should include investigating the requirement of metal 
ions such as Mg2+, K+, and Na+. As with its potential protection against 3 'blocked induced 
DNA damage (Izumi et al. 2000), our discovery of 3 'RNA phosphodiesterase activity 
suggests that APE1 may also protect against any 3 'blocked induced RNA damage.
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5.3 3' Exoribonuclease activity of APE1
Using a modified 5'-3 2P-labeled Oligo IA-RNA substrate, we have demonstrated for 
the first time the 3 'exoribonuclease activity of APE1, namely the ability to remove one 
ribonucleotide at 3 'overhang, which is demonstrated by the kinetic data presented (Figure 
10). However, the 3 'exoribonucleuse activity of APE1 against unstructured 
polyribonucleotides poly(A) is,poly(U) 15, and poly(C) 15 was very weak or negligible.
Our results suggest that any RNA is a potential substrate and their decay product with 
one ribonucleotide at 3 'overhang is subjected 3 'exoribonucleolytic cleavage by APE1. To 
test this hypothesis, future experiments should include the use of a variety of RNAs 
containing one ribonucleotide at 3 'overhang. Given that the APE1 has preferential 
3 'exoribonuclease activity against RNA with one nucleotide at 3 'overhang and weak to 
negligible exoribonuclease activity against polyribonucleotides, we propose that this 
ribonuclease activity of APE1 is biologically less significant in cells as compared to the other 
described ribonuclease activities of APE1.
5.4 Abasic RNA activity of APE1
Using 5'-3 2P-labeled 34-mer abasic RNA as substrate, APE1 exhibited both abasic 
RNA activity as well as RNA endoribonuclease activity. In an effort to further understand the 
ribonuclease activity of APE1, we determined the critical amino acid residues responsible for 
the abasic activity of APE1; and the RNA cleaving activities of the APE1 variants found in 
human populations. Interestingly, our preliminary results showed that a few of these variants 
(D148, L104, E126, N6 8 , F266, and D308) displayed significant reduction in their 
endoribonuclease activity in contrast to their functional abasic RNA activity relative to the 
wild-type APE1. From these results, we propose that APE1 uses different catalytic 
mechanism for removing a single nucleotide from abasic RNA and for cleaving internally 
within single-stranded region of RNA. The ability to cleave AP-site-containing RNA implies 
that APE1 can remove damaged templates from the endogenous pool. This activity provides 
a possible mechanism for the cell to eliminate damaged RNA prior to association with the 
ribosome and execution of non-productive translation, i.e., damage to rRNA and tRNA 
(Berquist et al. 2008; Korennykh et al 2007; Cochella et al 2005). Future in vivo work in
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understanding the role of these variants may generate valuable insights into understanding 
their associations with cancers.
5.5 Summary of ribonuclease activities of APE1
APE1 is a multifunctional protein implicated in many important cellular roles 
including abasic DNA endonuclease cleavage (Berquist et al. 2008), acting as a redox factor 
for many growth-related transcription factors (Evans et al. 2000), 3'-5' exonuclease activity 
for DNA (Chou et al. 2000), and endoribonuclease activity against both mRNA and abasic 
RNA in vitro (Barnes et al. 2009; Berquist et al. 2008). Some of the residues critical for the 
endoribonuclease activity for mRNA cleavage activity have been identified (Kim et al.
2011). These residues are very similar to the essential residues for AP-DNA cleavage 
activity, i.e., E96 and H309 (Kim et al. 2011), implying a shared binding and catalytic site 
between the DNA and RNA cleaving activities. However, the actual mechanism of cleavage 
between DNA and RNA is not likely the same due to the biochemical differences between 
DNA and RNA (Kim et al. 2011). Here we have identified the 3 'RNA phosphodiesterase 
activity of APE1 using single-stranded RNA substrates (Oligo LA, Oligo LA-RNA, Oligo LA- 
4 RNA), as well as weak 3'exoribonuclease activity of APE1 on 15 nt single stranded 
polyribonucleotides and Oligo IA-RNA. Furthermore, we assessed APE1 variants for abasic 
and endoribonuclease RNA cleaving activities of APE1 on 34-mer AP-ssRNA, which 
provided further support for its role in RNA metabolism. Table 12, summarizes the following 
ribonuclease activities of WT-APE1 and its structural variants.
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Table 12: Summary of ribonuclease activities of APE1 structural variants as compared to 
the 100% WT APE1 activity. Values are shown as percent reduction.
H309S H309N D283N N68A D308A D210N F266A D70A Y171F
Endoribonuclease 
activity against 
34-mer abasic 
RNA ^
MR MR AB MR MR AB MR UD AB
Endoribonuclease 
activity against 
182 nt c-myc 
RNA(d)
AB AB
(Barnes
2009)
AB AB AB AB AB AB AB
Abasic activity 
against abasic 
DNA(f) (%)
AB 0.001 10 0.17 4-20 0.004 16.7 14.6 0.02
(Kim (Chou (Hadi (Nguyen (Barzilay (Erzberger (Erzberger (Kim (Erzberger
2011) and 2000) 2000) 1995; 1999) 1998) 2011) 1999)
Cheng Erzberger
2003) 1999)
SmR = small reduction; MR= moderately reduced; SR = substantially reduced;
AB = abolished activity.
(a) Data obtained from Fig. 15a, b, c, d, and replicates (n=3).
(b) Qualitative data obtained from Fig. 22 -  25 (n=l).
(c) Data obtained from Fig. 15a, b, c, d, and replicates (n=3).
(d) Information obtained from the literature (Kim et al. 2009); fold reduction is converted to %.
(e) Qualitative data obtained from Fig. 22 -  25 (n=l).
(f) Information obtained from the literature; units of fold reduction are converted to %.
Using well-established methods for assessing various APE1 activities, the 
contributions of specific amino acid residues to AP-dsDNA incision, ssRNA cleavage, and 
AP-ssRNA incision were examined. Mutation at D210 and Y171 showed complete loss of 
endoribonuclease activity and abasic incision activities. Mutation at H309 and D70 showed
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significant reduction in all the listed nuclease activities of APE1. N6 8 A and D308A variants 
appeared to retain their AP-RNA incision activity on 34mer AP-RNA; and seemed to 
increase their endoribonuclease activity of APE1 on Oligo IA-4RNA; while significantly 
reducing their 3 phosphodiesterase, endoribonuclease AP-RNA, and AP-DNA incision 
activities of APE1 and also showed abrogation of endoribonuclease activity of APE1 on c- 
myc RNA. Mutation at F266 had moderate effect on the 3 phosphodiesterase, 
endoribonuclease activity on Oligo IA-4 RNA and AP-RNA incision activity on 34-mer AP- 
RNA; however it substantially reduced its endoribonuclease AJP-RNA and AP-DNA incision 
activities. Mutation at D283 substantially reduced in all the listed nuclease activities of 
APE1.
In summary, mutations at D210 and Y171, suggest that these two amino acid residues 
important for AP-dsDNA incision are also critical for the endoribonuclease activity of 
APEland its AP-RNA incision activity. Mutations at H309 and D70, suggest that these two 
residues are absolutely critical for the catalytic mechanism of APE1 in RNA degradation and 
during abasic incision of AP-RNA and AP-DNA. Mutations at N 6 8 A and D308A imply that 
the listed nuclease activities are distinct and most likely act via different mechanism. 
Mutation at F266 suggests that it plays a critical role in removing the abasic-site on AP-RNA 
and AP-DNA. Mutation at D283 appears to play an important role in the cleavage activities 
of APE1 on Oligo 1A-4 RNA, AP-RNA, AP-DNA and on c-myc RNA.
Nineteen human population variants of APE1 have been identified and several of 
these variants have been examined for perturbations in the biochemical functions of APE1 
demonstrating associations with disease. A summary of the effects of the population variants 
on the nuclease functions of APE1 are listed below in Table 13.
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Table 13: Summary of ribonuclease activity of APE1 human population variants as 
compared to the 100% WT APE1 activity. Values are shown as percent reduction.
D148E G306A G241R L104R E126D 051H I64V P311S
Endoribonuclease 
activity against 34- 
mer abasic RNA(b)
AB UD UD SR SR UD UD UD
Endoribonuclease 
activity against 182 
nt c-myc RNA(d)
Abasic activity 
against abasic DNA 94.4 107.2 108.7 56.7 60.4
(0
MR
(Kim
2009)
UD UD
SmR = small reduction; MR= moderately reduced; SR = substantially reduced;
IN = increased; AB = abolished activity.
(a) Data obtained from Fig. 16a, b, c, and replicates (n=3).
(b) Qualitative obtained from Fig. 18 — 23 (n=l).
(c) Data obtained from Fig. 16a, b, c, and replicates (n=3).
(d) Information obtained from the literature (Kim et al. 2009); fold reduction is converted to %.
(e) Qualitative data obtained from Fig. 20 -  21 (n=l).
<f) Information obtained from the literature (Hadi et al. 2000); fold reduction is converted to %.
Earlier studies on the human population variants of APE1 have focused on its AP- 
DNA endonuclease activity. The APE1 variants L104R and E126D showed 40-60% 
reduction in overall AP-DNA cleavage activity as compared to wild-type APE1 (Hadi et al. 
2000). In contrast, G241R had 10% increase in AP-DNA cleavage activity (Hadi et al. 
2000). Both D148E and G306A had identical cleavage ability as compared to the wild-type 
APE1 (Hadi et al. 2000).
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Experiments have been carried out to examine the effect of these variants on APE1 
endoribonuclease activity. When challenged with an 8 8 -nt long c-myc RNA substrate, the 
D148E, G241R and G306A variants showed decreased RNA cleaving activity as compared 
to that of wild-type APE1 (Kim et al. 2011). The L104R and E126D variants possess altered 
cleavage sites on the RNA substrate as both variants lost cleavage sites and gained additional 
unique cleavage sites, respectively, as compared to the cleavage sites of wild-type APE1 
(Kim et al. 2009).
In order to further understand the ribonuclease activity of APE1 we examined these 
variants for endoribonuclease activity and abasic incision activity against 34-mer AP-RNA. 
Many variants (D148, LI 04 and E l26) clearly retained abasic RNA activity but significantly 
lost endoribonuclease activity suggesting that these two nuclease activities are distinct and 
most likely act via different mechanism. The common APE1 variant D148E, occurring in 
about 50% of the population appears to show complete abrogation of its endoribonuclease 
activity on 34-mer AP-RNA, which is in agreement with the previous findings (Kim et al.
2011) where 182 nt c-myc RNA was used. Given that the AP-DNA activity of D148E,
L104R and E126D variants was not significantly altered (Hadi et al. 2000), this suggests that 
the link between these variants and human disease may be explained by their significantly 
altered ribonuclease activity (Kim et al. 2011).
5.6 Concluding remarks
This research was designed to identify and characterize the 3 RNA phosphodiesterase 
activity of APE1. This study provides the first demonstration of 3 'RNA phosphodiesterase 
activity of APE1 against three different RNA substrates. Upon endonucleolytically cleaving 
its RNA substrates, APE1 removes the phosphate group at the 3'end of decay product to 
generate 3 'hydroxyl group. Also, this thesis clearly demonstrated the distinct ribonuclease 
activity of APE1 and RNase A. RNase A is a very strong and active ribonuclease and a 
common contaminant in labs. The fact that both APE1 and RNase A share common cleavage 
sites has drawn skepticism regarding the ribonuclease activity of APE1. Hence, this study 
further confirms the ribonuclease activity of APE1 and underscores the significance of 
further studying the role of APE1 as an endoribonuclease and 3 'RNA phosphodiesterase in 
cells. This is particularly important because most if not all of APE1 variants present in the
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human population, including the most common D148E variant, have either abolished or 
significantly reduced in both endoribonuclease and 3'RNA phosphodiesterase activities.
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